Publications by authors named "M Liu"

26,725 Publications

  • Page 1 of 1

Acute effect of particulate matter pollution on hospital admissions for stroke among patients with type 2 diabetes in Beijing, China, from 2014 to 2018.

Ecotoxicol Environ Saf 2021 Apr 7;217:112201. Epub 2021 Apr 7.

School of Public Health, Capital Medical University, Beijing 100069, China; Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing 100069, China. Electronic address:

Background: The health effect of particulate matter pollution on stroke has been widely examined; however, the effect among patients with comorbid type 2 diabetes (T2D) in developing countries has remained largely unknown.

Methods: A time-series study was conducted to investigate the short-term effect of fine particulate matter (PM) and inhalable particulate matter (PM) on hospital admissions for stroke among patients with T2D in Beijing, China, from 2014 to 2018. An over-dispersed Poisson generalized additive model was employed to adjust for important covariates, such as weather conditions and long-term and seasonal trends.

Results: A total of 159,298 hospital admissions for stroke comorbid with T2D were reported. Approximately linear exposure-response curves were observed for PM and PM in relation to stroke admissions among T2D patients. A 10 μg/m increase in the four-day moving average of PM and PM was associated with 0.14% (95% confidence interval [CI]: 0.05-0.23%) and 0.14% (95% CI: 0.06-0.22%) incremental increases in stroke admissions among T2D patients, respectively. A 10 μg/m increase in PM in the two-day moving average corresponded to a 0.72% (95% CI: 0.02-1.42%) incremental increase in hemorrhagic stroke, and a 10 μg/m increase in PM in the four-day moving average corresponded to a 0.14% (95% CI: 0.06-0.22%) incremental increase in ischemic stroke.

Conclusions: High particulate matter might be a risk factor for stroke among patients with T2D. PM and PM have a linear exposure-response relationship with stroke among T2D patients. The study provided evidence of the risk of stroke due to particulate matter pollution among patients with comorbid T2D.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ecoenv.2021.112201DOI Listing
April 2021

Evaluating the impact of the travel ban within mainland China on the epidemic of the COVID-19.

Int J Infect Dis 2021 Apr 7. Epub 2021 Apr 7.

Lamps and Canadian Centre for Disease Modelling (CCDM), Department of Mathematics and Statistics, York University, Toronto, ON, M3J 1P3, Canada. Electronic address:

Objectives: The ongoing COVID-19 pandemic expanded its geographic distribution through the movement of humans and caused subsequent local outbreaks. Hence, it is essential to investigate how human mobility and travel ban affect the transmission and spatial spread while minimizing the impact on social activities and national economics.

Methods: We developed a mobility network model for spatial epidemics, explicitly taking into account time-varying inter-province and inner-province population flows, spatial heterogeneity in terms of disease transmission, as well as the impact of media reports. The model is applied to study the epidemic of the dynamic network of 30 provinces of mainland China. The model was calibrated using the publicly available incidence and movement data.

Results: We estimated that the second outbreak occurred approximately on February 24, 2020, and the cumulative number of cases as of March 15, 2020, increased by 290.1% (95% CI: (255.3%, 324.9%)) without a travel ban in mainland China (excluding Hubei and Tibet). We found that inter-province travel contributes more to the increase of cumulative number of cases than intra-province travel.

Conclusion: Our quantitative and qualitative research results suggest that the strict travel ban has successfully prevented a severe secondary outbreak in mainland China, which provides solutions for many countries and regions experiencing secondary outbreaks of COVID-19.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijid.2021.03.088DOI Listing
April 2021

Cost-effectiveness Analysis of Screening for Primary Aldosteronism in China.

Clin Endocrinol (Oxf) 2021 Apr 10. Epub 2021 Apr 10.

Department of Endocrinology, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China.

Objective: Primary aldosteronism (PA) is an underdiagnosed cause of hypertension. Although the medical costs will increase if all patients with elevated blood pressure are screened, the number of missed diagnosed patients with PA and the medical resources subsequently consumed by adverse cardiovascular and cerebrovascular events can be reduced. This study aimed to conduct economic evaluation PA screening strategies in Chinese patients with hypertension, that is, PA screening in patients with high-risk hypertension and all patients with hypertension, to determine the cost-effective method.

Methods: The decision tree and Markov model were constructed using TreeAge Pro 2020. Using the latter, a 30-year course of hypertension after different screening strategies was simulated, with a cycle of one year. The model parameters included epidemiological data, clinical efficacy, cost, and effectiveness. The total cost of treatment and quality-adjusted life-year (QALY) were simulated to conduct a cost-effectiveness analysis. Univariate and probabilistic sensitivity analyses of the model were also performed.

Results: PA screening patients with high-risk hypertension and all patients with hypertension obtained 15.75 and 15.77 QALYs and the costs were $2488.39 and $2482.15, respectively. The strategy of PA screening in all patients with hypertension is cost-saving, and produces more health outcomes. The sensitivity analysis showed that the results were reliable.

Conclusion: From the perspective of China's health system, the strategy of screening all hypertensive patients for PA may be more cost-effective than screening only high-risk patients and providing standard antihypertensive treatment for low-risk hypertensive patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/cen.14478DOI Listing
April 2021

Carotid intima-media thickness in patients with hyperuricemia: a systematic review and meta-analysis.

Aging Clin Exp Res 2021 Apr 9. Epub 2021 Apr 9.

Department of Rheumatology and Immunology, Affiliated Hospital of Southwest Medical University, 1 Xianglin Road, Luzhou, 646000, Sichuan, China.

Objective: Despite the high incidence and mortality of cardiovascular events in hyperuricemia patients, the role of serum uric acid in cardiovascular diseases is still controversial. The aim of this meta-analysis was to explore the difference of carotid intima-media thickness in hyperuricemia and control groups.

Methods: We performed this meta-analysis by searching the PubMed, Cochrane Library, Embase and Web of Science databases up to July 2020. The 95% confidence intervals and standard mean differences were calculated to analyze the differences in carotid intima-media thickness in hyperuricemia groups and control groups. Sensitivity analysis, subgroup analysis and meta-regression were used to explore the sources of heterogeneity. Publication bias was evaluated by funnel plot and Begg's regression test. We used Stata 14.0 software to complete our analyses.

Results: A total of 8 articles were included. The results showed that there was a significant increase in carotid intima-media thickness in the hyperuricemia groups compared with the control groups [SMD = 0.264, 95% CI (0.161-0.366), P < 0.001]. Subgroup analyses showed that age, sample size, blood pressure and body mass index were not the source of heterogeneity. Meta-regression enrolled the method of CIMT measurement, location, age, smoking and diabetes mellitus as categorical variables, but none of these factors was found to be significant in the model. The Begg's test value (P = 0.174) was greater than 0.05, indicating there was no publication bias.

Conclusion: The results showed that carotid intima-media thickness was increased in hyperuricemia patients compared with controls, which indicated that hyperuricemia patients may have a higher risk of cardiovascular diseases.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40520-021-01850-xDOI Listing
April 2021

A longitudinal study on emotional distress among local government staff seven years after the 2008 Wenchuan earthquake in China.

BMC Public Health 2021 Apr 9;21(1):702. Epub 2021 Apr 9.

Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Haidian District Huayuan North Road No. 51, Beijing, 100191, China.

Background: The current study examined the change in local government staff's emotional distress over 7 years after the 2008 Wenchuan earthquake, and the influence of earthquake exposure and professional quality of life (ProQOL) on emotional distress.

Methods: This longitudinal study assessed 250 participants at 1 year after the earthquake; 162 (64.8%) were followed up at 7 years. Emotional distress was assessed with the Self-Reporting Questionnaire (SRQ) at both time points. We assessed ProQOL, including compassion satisfaction, burnout, and secondary traumatic stress, and earthquake exposure at 1 year. Wilcoxon signed-rank tests were performed to test longitudinal changes in emotional distress. Hierarchical multiple regression was conducted to examine the effect of earthquake exposure and ProQOL.

Results: The positive screening rate of emotional distress (SRQ ≥ 8) was 37.6 and 15.4% at one and 7 years, respectively. Emotional distress scores declined over time (p < 0.001). Earthquake exposure and ProQOL predicted one-year (ps < 0.05) but not seven-year emotional distress, whereas burnout predicted both one-year (p = 0.018) and seven-year (p = 0.047) emotional distress.

Conclusions: Although emotional distress can recover over time, it persists even 7 years later. Actions to reduce burnout during the early stage of post-disaster rescue have long-term benefits to staff's psychological outcomes.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12889-021-10726-8DOI Listing
April 2021

Evolutionary research on the expansin protein family during the plant transition to land provides new insights into the development of Tartary buckwheat fruit.

BMC Genomics 2021 Apr 9;22(1):252. Epub 2021 Apr 9.

College of Life Science, Sichuan Agricultural University, Ya'an, 625014, China.

Background: Plant transitions to land require robust cell walls for regulatory adaptations and to resist changing environments. Cell walls provide essential plasticity for plant cell division and defense, which are often conferred by the expansin superfamily with cell wall-loosening functions. However, the evolutionary mechanisms of expansin during plant terrestrialization are unclear.

Results: Here, we identified 323 expansin proteins in 12 genomes from algae to angiosperms. Phylogenetic evolutionary, structural, motif gain and loss and Ka/Ks analyses indicated that highly conserved expansin proteins were already present in algae and expanded and purified after plant terrestrialization. We found that the expansion of the FtEXPA subfamily was caused by duplication events and that the functions of certain duplicated genes may have differentiated. More importantly, we generated space-time expression profiles and finally identified five differentially expressed FtEXPs in both large and small fruit Tartary buckwheat that may regulate fruit size by responding to indoleacetic acid.

Conclusions: A total of 323 expansin proteins from 12 representative plants were identified in our study during terrestrialization, and the expansin family that originated from algae expanded rapidly after the plants landed. The EXPA subfamily has more members and conservative evolution in angiosperms. FtEXPA1, FtEXPA11, FtEXPA12, FtEXPA19 and FtEXPA24 can respond to indole-3-acetic acid (IAA) signals and regulate fruit development. Our study provides a blueprint for improving the agronomic traits of Tartary buckwheat and a reference for defining the evolutionary history of the expansin family during plant transitions to land.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12864-021-07562-wDOI Listing
April 2021

The intracellular environment affects protein-protein interactions.

Proc Natl Acad Sci U S A 2021 Mar;118(11)

Key Laboratory of Magnetic Resonance in Biological Systems, State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Center for Magnetic Resonance in Wuhan, Wuhan National Laboratory for Optoelectronics, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences, 430071 Wuhan, China;

Protein-protein interactions are essential for life but rarely thermodynamically quantified in living cells. In vitro efforts show that protein complex stability is modulated by high concentrations of cosolutes, including synthetic polymers, proteins, and cell lysates via a combination of hard-core repulsions and chemical interactions. We quantified the stability of a model protein complex, the A34F GB1 homodimer, in buffer, cells and oocytes. The complex is more stable in cells than in buffer and more stable in oocytes than Studies of several variants show that increasing the negative charge on the homodimer surface increases stability in cells. These data, taken together with the fact that oocytes are less crowded than cells, lead to the conclusion that chemical interactions are more important than hard-core repulsions under physiological conditions, a conclusion also gleaned from studies of protein stability in cells. Our studies have implications for understanding how promiscuous-and specific-interactions coherently evolve for a protein to properly function in the crowded cellular environment.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.2019918118DOI Listing
March 2021

Non-optimum temperature-related mortality burden in China: Addressing the dual influences of climate change and urban heat islands.

Sci Total Environ 2021 Mar 26;782:146760. Epub 2021 Mar 26.

State Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University, Nanjing, Jiangsu, China. Electronic address:

Under the dual effects of climate change and urban heat islands (UHI), non-optimum temperature-related mortality burdens are complex and uncertain, and are rarely discussed in China. In this study, by applying city-specific exposure-response functions to multiple temperature and population projections under different climate and urbanization scenarios, we comprehensively assessed the non-optimum temperature-related mortality burdens in China from 2000 to 2050. Our results showed that temperature-related deaths will decrease from 1.19 million in 2010 to 1.08-1.17 million in 2050, with the exception of the most populous scenario. Excess deaths attributable to non-optimal temperatures under representative concentration pathway 8.5 (RCP8.5) were 2.35% greater than those under RCP4.5. This indicates that the surge in heat-related deaths caused by climate change will be offset by the reduction in cold-related deaths. As the climate changes, high-risk areas will be confronted with more severe health challenges, which requires health protection resource relocation strategies. Simultaneously, the net effects of UHIs are beneficial in the historical periods, preventing 3493 (95% CI: 22-6964) deaths in 2000. But UHIs will cause an additional 6951 (95% CI: -17,637-31,539, SSP4-RCP4.5) to 17,041 (95% CI: -10,516-44,598, SSP5-RCP8.5) deaths in 2050. The heavier health burden in RCP8.5 than RCP4.5 indicates that a warmer climate aggravates the negative effects of UHIs. Considering the synergistic behavior of climate change and UHIs, UHI mitigation strategies should not be developed without considering climate change. Moreover, the mortality burden exhibited strong spatial variations, with heavy burdens concentrated in the hotspots including Beijing-Tianjin Metropolitan Region, Yangtze River Delta, Chengdu-Chongqing City Group, Guangzhou, Wuhan, Xi'an, Shandong, and Henan. These hotspots should be priority areas for the allocation of the national medical resources to provide effective public health interventions.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.scitotenv.2021.146760DOI Listing
March 2021

Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates.

Virol Sin 2021 Apr 9. Epub 2021 Apr 9.

Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.

The ongoing coronavirus disease 2019 (COVID-19) pandemic caused more than 96 million infections and over 2 million deaths worldwide so far. However, there is no approved vaccine available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease causative agent. Vaccine is the most effective approach to eradicate a pathogen. The tests of safety and efficacy in animals are pivotal for developing a vaccine and before the vaccine is applied to human populations. Here we evaluated the safety, immunogenicity, and efficacy of an inactivated vaccine based on the whole viral particles in human ACE2 transgenic mouse and in non-human primates. Our data showed that the inactivated vaccine successfully induced SARS-CoV-2-specific neutralizing antibodies in mice and non-human primates, and subsequently provided partial (in low dose) or full (in high dose) protection of challenge in the tested animals. In addition, passive serum transferred from vaccine-immunized mice could also provide full protection from SARS-CoV-2 infection in mice. These results warranted positive outcomes in future clinical trials in humans.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12250-021-00376-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034048PMC
April 2021

Changes in Incidence and Epidemiological Characteristics of Pulmonary Tuberculosis in Mainland China, 2005-2016.

JAMA Netw Open 2021 Apr 1;4(4):e215302. Epub 2021 Apr 1.

School of Public Health, Capital Medical University, Beijing, China.

Importance: The World Health Organization End TB (Tuberculosis) Strategy aims to decrease the global incidence and mortality of TB by 90% and 95%, respectively, as of 2035.

Objective: To characterize the recent epidemiological trend of pulmonary TB (PTB) in mainland China based on the national surveillance data.

Design, Setting, And Participants: This cross-sectional study collected demographic and clinical data of all patients reported in the national Tuberculosis Information Management System of China from January 1, 2005, to November 21, 2016. Data were analyzed from December 1, 2019, to July 31, 2020.

Exposures: Pulmonary TB was defined as bacteriologically confirmed or clinically diagnosed TB in the lung parenchyma or the tracheobronchial tree.

Main Outcomes And Measures: Temporal and spatial variation of annual incidence and demographic features of PTB in mainland China.

Results: In total, 10 582 903 patients with PTB were reported in mainland China from 2005 to 2016. The median age of patients with PTB was 46 (interquartile range [IQR], 30-61) years, and 28.53% were 60 years or older. Most patients with PTB were male (69.8%) and farmers or herders (70.0%). The mean (SD) incidence of PTB was 66.61 (8.09) per 100 000 population. The annual incidence decreased from 72.95 per 100 000 population in 2005 to 52.18 per 100 000 population in 2016, and the reduction was greater in the eastern and central regions (31.6%; from 69.43 to 47.48 per 100 000 population) than in the western region (21.0%; from 82.06 to 64.82 per 100 000 population). Xinjiang Uygur Autonomous Region (135.03 per 100 000 population), Guizhou Province (115.98 per 100 000 population), and the Tibet Autonomous Region (101.98 per 100 000 population) had the highest mean annual incidences. The median time from onset of illness to diagnosis decreased from 36 (IQR, 16-92) days from 2005 to 2007 to 31 (IQR, 15-63) days in 2008 and later (P < .001) and was longer in the western region than in the eastern and central regions (41 [IQR, 20-91] vs 30 [IQR, 13-61] days; P < .001).

Conclusions And Relevance: Although this study found that the incidence of PTB in mainland China showed a downward trend from 2005 to 2016, to achieve the World Health Organization 2035 goal, innovative and more efficient prevention and control strategies are needed, particularly among the most susceptible population, that is, farmers and herders in western China.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamanetworkopen.2021.5302DOI Listing
April 2021

Squamous cell carcinoma subverts adjacent histologically normal epithelium to promote lateral invasion.

J Exp Med 2021 Jun;218(6)

Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI.

Recurrent and new tumors, attributed in part to lateral invasion, are frequent in squamous cell carcinomas and lead to poor survival. We identified a mechanism by which cancer subverts adjacent histologically normal epithelium to enable small clusters of cancer cells to burrow undetected under adjacent histologically normal epithelium. We show that suppression of DMBT1 within cancer promotes aggressive invasion and metastasis in vivo and is associated with metastasis in patients. Cancer cells via TGFβ1 and TNFα also suppress DMBT1 in adjacent histologically normal epithelium, thereby subverting it to promote invasion of a small population of tumor cells. The sufficiency of DMBT1 in this process is demonstrated by significantly higher satellite tumor nests in Dmbt1-/- compared with wild-type mice. Moreover, in patients, invasion of small tumor nests under adjacent histologically normal epithelium is associated with increased risk for recurrence and shorter disease-free survival. This study demonstrates a crucial role of adjacent histologically normal epithelium in invasion and its important role in the tumor microenvironment and opens new possibilities for therapeutic strategies that reduce tumor recurrence.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20200944DOI Listing
June 2021

[Comparison of efficacy between veno-venous extracorporeal membrane oxygenation (VV-ECMO) and VV-ECMO combined with prone position ventilation for the treatment of acute respiratory distress syndrome].

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2021 Mar;33(3):293-298

Department of Critical Care Medicine, Liuzhou People's Hospital, Liuzhou 545006, Guangxi Zhuang Autonomous Region, China. Corresponding author: Wang Xiaoyuan, Email:

Objective: To observe the effects of veno-venous extracorporeal membrane oxygenation (VV-ECMO) combined with prone position ventilation (PPV) on oxygenation index (PaO/FiO), respiratory compliance (Crs) and vasoactive inotropic score (VIS) in severe acute respiratory distress syndrome (ARDS) patients.

Methods: Eighteen patients with severe ARDS requiring VV-ECMO support in Liuzhou People's Hospital from June 2018 to April 2020 were selected for retrospective analysis, and 8 patients among of these cases received PPV after VV-ECMO. The differences in PaO/FiO, VIS and Crs before and 1, 2 or 3 days after treatment were compared between VV-ECMO group and VV-ECMO combined with PPV group, as well as the differences in these indices before PPV and 2 hours after PPV daily in VV-ECMO combined with PPV group. The incidence of adverse events in two groups were also observed.

Results: Before treatment, there was no significant difference in PaO/FiO, Crs between two groups. Over time, PaO/FiO and Crs increased and VIS decreased in both groups. Compared with before treatment, there were statistically significant differences in PaO/FiO and VIS from 1 day after treatment [PaO/FiO (mmHg, 1 mmHg = 0.133 kPa): VV-ECMO group was 197.75±39.80 vs. 75.57±7.44, VV-ECMO combined with PPV group was 255.20±31.92 vs. 68.24±11.64; VIS: VV-ECMO group was 5.51±3.72 vs. 10.20±7.10, VV-ECMO combined with PPV group was 6.73±3.32 vs. 14.50±2.48, all P < 0.05], up to 3 days after treatment [PaO/FiO (mmHg): VV-ECMO group was 231.96±32.76 vs. 75.57±7.44, VV-ECMO combined with PPV group was 285.61±19.40 vs. 68.24±11.64; VIS: VV-ECMO group was 2.26±1.90 vs. 10.20±7.10, VV-ECMO combined with PPV group was 2.13±1.55 vs. 14.50±2.48, all P < 0.05], and the PaO/FiO 1 day and 3 days after treatment in VV-ECMO combined with PPV group were significantly higher than those in VV-ECMO group (mmHg: after 1 day of treatment was 255.20±31.92 vs. 197.75±39.80, after 3 days of treatment was 285.61±19.40 vs. 231.96±32.76, both P < 0.05). Before treatment, Crs of VV-ECMO combined with PPV group was significantly lower than that of VV-ECMO group (mL/cmHO: 17.91±0.82 vs. 20.54±1.26, P < 0.05). From 1 day after treatment, the Crs in VV-ECMO combined with PPV group was significantly higher than that before treatment (mL/cmHO: 21.20±1.50 vs. 17.91±0.82), the peak value was (24.93±2.18) mL/cmHO on 3 days after treatment, however, there was no significant difference between the two groups (all P < 0.05). In VV-ECMO combined with PPV group, compared with before PPV treatment, the PaO/FiO and Crs of 2 hours after PPV treatment in 1, 2 and 3 days were significantly rose, and it reached the highest level in 3 days [PaO/FiO (mmHg): 285.61±19.40 vs. 189.91±28.34, Crs (mL/cmHO): 24.93±2.18 vs. 23.35±1.45, both P < 0.05]; the VIS was only increased in 2 hours after PPV treatment on the first day than before (6.73±3.32 vs. 6.38±3.22, P < 0.05). There were no related serious adverse events happened after PPV treatment.

Conclusions: The combination of PPV during VV-ECMO could further increase PaO/FiO, improve hypoxemia and implement further protective lung ventilation to reduce the potential hazards during mechanical ventilation. In addition, no serious adverse events were observed in this study, suggesting PPV is safe during VV-ECMO.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn121430-20200805-00563DOI Listing
March 2021

Search for Dark Matter Produced in Association with a Dark Higgs Boson Decaying into W^{±}W^{∓} or ZZ in Fully Hadronic Final States from sqrt[s]=13  TeV pp Collisions Recorded with the ATLAS Detector.

Authors:
G Aad B Abbott D C Abbott A Abed Abud K Abeling D K Abhayasinghe S H Abidi O S AbouZeid N L Abraham H Abramowicz H Abreu Y Abulaiti B S Acharya B Achkar L Adam C Adam Bourdarios L Adamczyk L Adamek J Adelman A Adiguzel S Adorni T Adye A A Affolder Y Afik C Agapopoulou M N Agaras A Aggarwal C Agheorghiesei J A Aguilar-Saavedra A Ahmad F Ahmadov W S Ahmed X Ai G Aielli S Akatsuka M Akbiyik T P A Åkesson E Akilli A V Akimov K Al Khoury G L Alberghi J Albert M J Alconada Verzini S Alderweireldt M Aleksa I N Aleksandrov C Alexa T Alexopoulos A Alfonsi F Alfonsi M Alhroob B Ali S Ali M Aliev G Alimonti C Allaire B M M Allbrooke B W Allen P P Allport A Aloisio F Alonso C Alpigiani E Alunno Camelia M Alvarez Estevez M G Alviggi Y Amaral Coutinho A Ambler L Ambroz C Amelung D Amidei S P Amor Dos Santos S Amoroso C S Amrouche F An C Anastopoulos N Andari T Andeen J K Anders S Y Andrean A Andreazza V Andrei C R Anelli S Angelidakis A Angerami A V Anisenkov A Annovi C Antel M T Anthony E Antipov M Antonelli D J A Antrim F Anulli M Aoki J A Aparisi Pozo M A Aparo L Aperio Bella N Aranzabal V Araujo Ferraz R Araujo Pereira C Arcangeletti A T H Arce J-F Arguin S Argyropoulos J-H Arling A J Armbruster A Armstrong O Arnaez H Arnold Z P Arrubarrena Tame G Artoni H Asada K Asai S Asai T Asawatavonvanich N Asbah E M Asimakopoulou L Asquith J Assahsah K Assamagan R Astalos R J Atkin M Atkinson N B Atlay H Atmani P A Atmasiddha K Augsten V A Austrup G Avolio M K Ayoub G Azuelos D Babal H Bachacou K Bachas F Backman P Bagnaia M Bahmani H Bahrasemani A J Bailey V R Bailey J T Baines C Bakalis O K Baker P J Bakker E Bakos D Bakshi Gupta S Balaji R Balasubramanian E M Baldin P Balek F Balli W K Balunas J Balz E Banas M Bandieramonte A Bandyopadhyay Sw Banerjee L Barak W M Barbe E L Barberio D Barberis M Barbero G Barbour T Barillari M-S Barisits J Barkeloo T Barklow R Barnea B M Barnett R M Barnett Z Barnovska-Blenessy A Baroncelli G Barone A J Barr L Barranco Navarro F Barreiro J Barreiro Guimarães da Costa U Barron S Barsov F Bartels R Bartoldus G Bartolini A E Barton P Bartos A Basalaev A Basan A Bassalat M J Basso R L Bates S Batlamous J R Batley B Batool M Battaglia M Bauce F Bauer P Bauer H S Bawa A Bayirli J B Beacham T Beau P H Beauchemin F Becherer P Bechtle H C Beck H P Beck K Becker C Becot A Beddall A J Beddall V A Bednyakov M Bedognetti C P Bee T A Beermann M Begalli M Begel A Behera J K Behr F Beisiegel M Belfkir A S Bell G Bella L Bellagamba A Bellerive P Bellos K Beloborodov K Belotskiy N L Belyaev D Benchekroun N Benekos Y Benhammou D P Benjamin M Benoit J R Bensinger S Bentvelsen L Beresford M Beretta D Berge E Bergeaas Kuutmann N Berger B Bergmann L J Bergsten J Beringer S Berlendis G Bernardi C Bernius F U Bernlochner T Berry P Berta A Berthold I A Bertram O Bessidskaia Bylund N Besson S Bethke A Betti A J Bevan J Beyer S Bhatta D S Bhattacharya P Bhattarai V S Bhopatkar R Bi R M Bianchi O Biebel D Biedermann R Bielski K Bierwagen N V Biesuz M Biglietti T R V Billoud M Bindi A Bingul C Bini S Biondi C J Birch-Sykes M Birman T Bisanz J P Biswal D Biswas A Bitadze C Bittrich K Bjørke T Blazek I Bloch C Blocker A Blue U Blumenschein G J Bobbink V S Bobrovnikov S S Bocchetta D Bogavac A G Bogdanchikov C Bohm V Boisvert P Bokan T Bold A E Bolz M Bomben M Bona J S Bonilla M Boonekamp C D Booth A G Borbély H M Borecka-Bielska L S Borgna A Borisov G Borissov D Bortoletto D Boscherini M Bosman J D Bossio Sola K Bouaouda J Boudreau E V Bouhova-Thacker D Boumediene A Boveia J Boyd D Boye I R Boyko A J Bozson J Bracinik N Brahimi G Brandt O Brandt F Braren B Brau J E Brau W D Breaden Madden K Brendlinger R Brener L Brenner R Brenner S Bressler B Brickwedde D L Briglin D Britton D Britzger I Brock R Brock G Brooijmans W K Brooks E Brost P A Bruckman de Renstrom B Brüers D Bruncko A Bruni G Bruni M Bruschi N Bruscino L Bryngemark T Buanes Q Buat P Buchholz A G Buckley I A Budagov M K Bugge O Bulekov B A Bullard T J Burch S Burdin C D Burgard A M Burger B Burghgrave J T P Burr C D Burton J C Burzynski V Büscher E Buschmann P J Bussey J M Butler C M Buttar J M Butterworth P Butti W Buttinger C J Buxo Vazquez A Buzatu A R Buzykaev G Cabras S Cabrera Urbán D Caforio H Cai V M M Cairo O Cakir N Calace P Calafiura G Calderini P Calfayan G Callea L P Caloba A Caltabiano S Calvente Lopez D Calvet S Calvet T P Calvet M Calvetti R Camacho Toro S Camarda D Camarero Munoz P Camarri M T Camerlingo D Cameron C Camincher S Campana M Campanelli A Camplani V Canale A Canesse M Cano Bret J Cantero T Cao Y Cao M Capua R Cardarelli F Cardillo G Carducci I Carli T Carli G Carlino B T Carlson E M Carlson L Carminati R M D Carney S Caron E Carquin S Carrá G Carratta J W S Carter T M Carter M P Casado A F Casha E G Castiglia F L Castillo L Castillo Garcia V Castillo Gimenez N F Castro A Catinaccio J R Catmore A Cattai V Cavaliere V Cavasinni E Celebi F Celli K Cerny A S Cerqueira A Cerri L Cerrito F Cerutti A Cervelli S A Cetin Z Chadi D Chakraborty J Chan W S Chan W Y Chan J D Chapman B Chargeishvili D G Charlton T P Charman M Chatterjee C C Chau S Che S Chekanov S V Chekulaev G A Chelkov B Chen C Chen C H Chen H Chen H Chen J Chen J Chen J Chen S Chen S J Chen X Chen Y Chen Y-H Chen H C Cheng H J Cheng A Cheplakov E Cheremushkina R Cherkaoui El Moursli E Cheu K Cheung T J A Chevalérias L Chevalier V Chiarella G Chiarelli G Chiodini A S Chisholm A Chitan I Chiu Y H Chiu M V Chizhov K Choi A R Chomont Y Chou Y S Chow L D Christopher M C Chu X Chu J Chudoba J J Chwastowski L Chytka D Cieri K M Ciesla V Cindro I A Cioară A Ciocio F Cirotto Z H Citron M Citterio D A Ciubotaru B M Ciungu A Clark P J Clark S E Clawson C Clement Y Coadou M Cobal A Coccaro J Cochran R Coelho Lopes De Sa H Cohen A E C Coimbra B Cole A P Colijn J Collot P Conde Muiño S H Connell I A Connelly S Constantinescu F Conventi A M Cooper-Sarkar F Cormier K J R Cormier L D Corpe M Corradi E E Corrigan F Corriveau M J Costa F Costanza D Costanzo G Cowan J W Cowley J Crane K Cranmer R A Creager S Crépé-Renaudin F Crescioli M Cristinziani V Croft G Crosetti A Cueto T Cuhadar Donszelmann H Cui A R Cukierman W R Cunningham S Czekierda P Czodrowski M M Czurylo M J Da Cunha Sargedas De Sousa J V Da Fonseca Pinto C Da Via W Dabrowski F Dachs T Dado S Dahbi T Dai C Dallapiccola M Dam G D'amen V D'Amico J Damp J R Dandoy M F Daneri M Danninger V Dao G Darbo O Dartsi A Dattagupta T Daubney S D'Auria C David T Davidek D R Davis I Dawson K De R De Asmundis M De Beurs S De Castro N De Groot P de Jong H De la Torre A De Maria D De Pedis A De Salvo U De Sanctis M De Santis A De Santo J B De Vivie De Regie D V Dedovich A M Deiana J Del Peso Y Delabat Diaz D Delgove F Deliot C M Delitzsch M Della Pietra D Della Volpe A Dell'Acqua L Dell'Asta M Delmastro C Delporte P A Delsart S Demers M Demichev G Demontigny S P Denisov L D'Eramo D Derendarz J E Derkaoui F Derue P Dervan K Desch K Dette C Deutsch M R Devesa P O Deviveiros F A Di Bello A Di Ciaccio L Di Ciaccio W K Di Clemente C Di Donato A Di Girolamo G Di Gregorio A Di Luca B Di Micco R Di Nardo K F Di Petrillo R Di Sipio C Diaconu F A Dias T Dias Do Vale M A Diaz F G Diaz Capriles J Dickinson M Didenko E B Diehl J Dietrich S Díez Cornell C Diez Pardos A Dimitrievska W Ding J Dingfelder S J Dittmeier F Dittus F Djama T Djobava J I Djuvsland M A B Do Vale M Dobre D Dodsworth C Doglioni J Dolejsi Z Dolezal M Donadelli B Dong J Donini A D'onofrio M D'Onofrio J Dopke A Doria M T Dova A T Doyle E Drechsler E Dreyer T Dreyer A S Drobac D Du T A du Pree Y Duan F Dubinin M Dubovsky A Dubreuil E Duchovni G Duckeck O A Ducu D Duda A Dudarev A C Dudder E M Duffield M D'uffizi L Duflot M Dührssen C Dülsen M Dumancic A E Dumitriu M Dunford S Dungs A Duperrin H Duran Yildiz M Düren A Durglishvili D Duschinger B Dutta D Duvnjak G I Dyckes M Dyndal S Dysch B S Dziedzic M G Eggleston T Eifert G Eigen K Einsweiler T Ekelof H El Jarrari V Ellajosyula M Ellert F Ellinghaus A A Elliot N Ellis J Elmsheuser M Elsing D Emeliyanov A Emerman Y Enari M B Epland J Erdmann A Ereditato P A Erland M Errenst M Escalier C Escobar O Estrada Pastor E Etzion G E Evans H Evans M O Evans A Ezhilov F Fabbri L Fabbri V Fabiani G Facini R M Fakhrutdinov S Falciano P J Falke S Falke J Faltova Y Fang Y Fang G Fanourakis M Fanti M Faraj A Farbin A Farilla E M Farina T Farooque S M Farrington P Farthouat F Fassi P Fassnacht D Fassouliotis M Faucci Giannelli W J Fawcett L Fayard O L Fedin W Fedorko A Fehr M Feickert L Feligioni A Fell C Feng M Feng M J Fenton A B Fenyuk S W Ferguson J Ferrando A Ferrari P Ferrari R Ferrari D E Ferreira de Lima A Ferrer D Ferrere C Ferretti F Fiedler A Filipčič F Filthaut K D Finelli M C N Fiolhais L Fiorini F Fischer J Fischer W C Fisher T Fitschen I Fleck P Fleischmann T Flick B M Flierl L Flores L R Flores Castillo F M Follega N Fomin J H Foo G T Forcolin B C Forland A Formica F A Förster A C Forti E Fortin M G Foti D Fournier H Fox P Francavilla S Francescato M Franchini S Franchino D Francis L Franco L Franconi M Franklin G Frattari A N Fray P M Freeman B Freund W S Freund E M Freundlich D C Frizzell D Froidevaux J A Frost M Fujimoto C Fukunaga E Fullana Torregrosa T Fusayasu J Fuster A Gabrielli A Gabrielli S Gadatsch P Gadow G Gagliardi L G Gagnon G E Gallardo E J Gallas B J Gallop R Gamboa Goni K K Gan S Ganguly J Gao Y Gao Y S Gao F M Garay Walls C García J E García Navarro J A García Pascual C Garcia-Argos M Garcia-Sciveres R W Gardner N Garelli S Gargiulo C A Garner V Garonne S J Gasiorowski P Gaspar A Gaudiello G Gaudio P Gauzzi I L Gavrilenko A Gavrilyuk C Gay G Gaycken E N Gazis A A Geanta C M Gee C N P Gee J Geisen M Geisen C Gemme M H Genest C Geng S Gentile S George T Geralis L O Gerlach P Gessinger-Befurt G Gessner M Ghasemi Bostanabad M Ghneimat A Ghosh A Ghosh B Giacobbe S Giagu N Giangiacomi P Giannetti A Giannini G Giannini S M Gibson M Gignac D T Gil B J Gilbert D Gillberg G Gilles N E K Gillwald D M Gingrich M P Giordani P F Giraud G Giugliarelli D Giugni F Giuli S Gkaitatzis I Gkialas E L Gkougkousis P Gkountoumis L K Gladilin C Glasman J Glatzer P C F Glaysher A Glazov G R Gledhill I Gnesi M Goblirsch-Kolb D Godin S Goldfarb T Golling D Golubkov A Gomes R Goncalves Gama R Gonçalo G Gonella L Gonella A Gongadze F Gonnella J L Gonski S González de la Hoz S Gonzalez Fernandez R Gonzalez Lopez C Gonzalez Renteria R Gonzalez Suarez S Gonzalez-Sevilla G R Gonzalvo Rodriguez L Goossens N A Gorasia P A Gorbounov H A Gordon B Gorini E Gorini A Gorišek A T Goshaw M I Gostkin C A Gottardo M Gouighri A G Goussiou N Govender C Goy I Grabowska-Bold E C Graham J Gramling E Gramstad S Grancagnolo M Grandi V Gratchev P M Gravila F G Gravili C Gray H M Gray C Grefe K Gregersen I M Gregor P Grenier K Grevtsov C Grieco N A Grieser A A Grillo K Grimm S Grinstein J-F Grivaz S Groh E Gross J Grosse-Knetter Z J Grout C Grud A Grummer J C Grundy L Guan W Guan C Gubbels J Guenther A Guerguichon J G R Guerrero Rojas F Guescini D Guest R Gugel A Guida T Guillemin S Guindon J Guo W Guo Y Guo Z Guo R Gupta S Gurbuz G Gustavino M Guth P Gutierrez C Gutschow C Guyot C Gwenlan C B Gwilliam E S Haaland A Haas C Haber H K Hadavand A Hadef M Haleem J Haley J J Hall G Halladjian G D Hallewell K Hamano H Hamdaoui M Hamer G N Hamity K Han L Han L Han S Han Y F Han K Hanagaki M Hance D M Handl M D Hank R Hankache E Hansen J B Hansen J D Hansen M C Hansen P H Hansen E C Hanson K Hara T Harenberg S Harkusha P F Harrison N M Hartman N M Hartmann Y Hasegawa A Hasib S Hassani S Haug R Hauser M Havranek C M Hawkes R J Hawkings S Hayashida D Hayden C Hayes R L Hayes C P Hays J M Hays H S Hayward S J Haywood F He Y He M P Heath V Hedberg A L Heggelund N D Hehir C Heidegger K K Heidegger W D Heidorn J Heilman S Heim T Heim B Heinemann J G Heinlein J J Heinrich L Heinrich J Hejbal L Helary A Held S Hellesund C M Helling S Hellman C Helsens R C W Henderson L Henkelmann A M Henriques Correia H Herde Y Hernández Jiménez H Herr M G Herrmann T Herrmann G Herten R Hertenberger L Hervas G G Hesketh N P Hessey H Hibi S Higashino E Higón-Rodriguez K Hildebrand J C Hill K K Hill K H Hiller S J Hillier M Hils I Hinchliffe F Hinterkeuser M Hirose S Hirose D Hirschbuehl B Hiti O Hladik J Hobbs R Hobincu N Hod M C Hodgkinson A Hoecker D Hohn D Hohov T Holm T R Holmes M Holzbock L B A H Hommels T M Hong J C Honig A Hönle B H Hooberman W H Hopkins Y Horii P Horn L A Horyn S Hou A Hoummada J Howarth J Hoya M Hrabovsky J Hrivnac A Hrynevich T Hryn'ova P J Hsu S-C Hsu Q Hu S Hu Y F Hu D P Huang X Huang Y Huang Y Huang Z Hubacek F Hubaut M Huebner F Huegging T B Huffman M Huhtinen R Hulsken R F H Hunter N Huseynov J Huston J Huth R Hyneman S Hyrych G Iacobucci G Iakovidis I Ibragimov L Iconomidou-Fayard P Iengo R Ignazzi R Iguchi T Iizawa Y Ikegami M Ikeno N Ilic F Iltzsche H Imam G Introzzi M Iodice K Iordanidou V Ippolito M F Isacson M Ishino W Islam C Issever S Istin J M Iturbe Ponce R Iuppa A Ivina J M Izen V Izzo P Jacka P Jackson R M Jacobs B P Jaeger V Jain G Jäkel K B Jakobi K Jakobs T Jakoubek J Jamieson K W Janas R Jansky M Janus P A Janus G Jarlskog A E Jaspan N Javadov T Javůrek M Javurkova F Jeanneau L Jeanty J Jejelava P Jenni N Jeong S Jézéquel J Jia Z Jia H Jiang Y Jiang Z Jiang S Jiggins F A Jimenez Morales J Jimenez Pena S Jin A Jinaru O Jinnouchi H Jivan P Johansson K A Johns C A Johnson E Jones R W L Jones S D Jones T J Jones J Jovicevic X Ju J J Junggeburth A Juste Rozas A Kaczmarska M Kado H Kagan M Kagan A Kahn C Kahra T Kaji E Kajomovitz C W Kalderon A Kaluza A Kamenshchikov M Kaneda N J Kang S Kang Y Kano J Kanzaki L S Kaplan D Kar K Karava M J Kareem I Karkanias S N Karpov Z M Karpova V Kartvelishvili A N Karyukhin E Kasimi A Kastanas C Kato J Katzy K Kawade K Kawagoe T Kawaguchi T Kawamoto G Kawamura E F Kay F I Kaya S Kazakos V F Kazanin J M Keaveney R Keeler J S Keller E Kellermann D Kelsey J J Kempster J Kendrick K E Kennedy O Kepka S Kersten B P Kerševan S Ketabchi Haghighat F Khalil-Zada M Khandoga A Khanov A G Kharlamov T Kharlamova E E Khoda T J Khoo G Khoriauli E Khramov J Khubua S Kido M Kiehn E Kim Y K Kim N Kimura A Kirchhoff D Kirchmeier J Kirk A E Kiryunin T Kishimoto D P Kisliuk V Kitali C Kitsaki O Kivernyk T Klapdor-Kleingrothaus M Klassen C Klein M H Klein M Klein U Klein K Kleinknecht P Klimek A Klimentov F Klimpel T Klingl T Klioutchnikova F F Klitzner P Kluit S Kluth E Kneringer E B F G Knoops A Knue D Kobayashi M Kobel M Kocian T Kodama P Kodys D M Koeck P T Koenig T Koffas N M Köhler M Kolb I Koletsou T Komarek T Kondo K Köneke A X Y Kong A C König T Kono V Konstantinides N Konstantinidis B Konya R Kopeliansky S Koperny K Korcyl K Kordas G Koren A Korn I Korolkov E V Korolkova N Korotkova O Kortner S Kortner V V Kostyukhin A Kotsokechagia A Kotwal A Koulouris A Kourkoumeli-Charalampidi C Kourkoumelis E Kourlitis V Kouskoura R Kowalewski W Kozanecki A S Kozhin V A Kramarenko G Kramberger D Krasnopevtsev M W Krasny A Krasznahorkay D Krauss J A Kremer J Kretzschmar K Kreul P Krieger F Krieter S Krishnamurthy A Krishnan M Krivos K Krizka K Kroeninger H Kroha J Kroll J Kroll K S Krowpman U Kruchonak H Krüger N Krumnack M C Kruse J A Krzysiak A Kubota O Kuchinskaia S Kuday D Kuechler J T Kuechler S Kuehn T Kuhl V Kukhtin Y Kulchitsky S Kuleshov Y P Kulinich M Kuna A Kupco T Kupfer O Kuprash H Kurashige L L Kurchaninov Y A Kurochkin A Kurova M G Kurth E S Kuwertz M Kuze A K Kvam J Kvita T Kwan C Lacasta F Lacava D P J Lack H Lacker D Lacour E Ladygin R Lafaye B Laforge T Lagouri S Lai I K Lakomiec J E Lambert S Lammers W Lampl C Lampoudis E Lançon U Landgraf M P J Landon V S Lang J C Lange R J Langenberg A J Lankford F Lanni K Lantzsch A Lanza A Lapertosa J F Laporte T Lari F Lasagni Manghi M Lassnig V Latonova T S Lau A Laudrain A Laurier M Lavorgna S D Lawlor M Lazzaroni B Le E Le Guirriec A Lebedev M LeBlanc T LeCompte F Ledroit-Guillon A C A Lee C A Lee G R Lee L Lee S C Lee S Lee B Lefebvre H P Lefebvre M Lefebvre C Leggett K Lehmann N Lehmann G Lehmann Miotto W A Leight A Leisos M A L Leite C E Leitgeb R Leitner K J C Leney T Lenz S Leone C Leonidopoulos A Leopold C Leroy R Les C G Lester M Levchenko J Levêque D Levin L J Levinson D J Lewis B Li B Li C-Q Li F Li H Li H Li J Li K Li L Li M Li Q Y Li S Li X Li Y Li Z Li Z Li Z Li Z Li Z Liang M Liberatore B Liberti K Lie S Lim C Y Lin K Lin R A Linck R E Lindley J H Lindon A Linss A L Lionti E Lipeles A Lipniacka T M Liss A Lister J D Little B Liu B L Liu H B Liu J B Liu J K K Liu K Liu M Liu M Y Liu P Liu X Liu Y Liu Y Liu Y L Liu Y W Liu M Livan A Lleres J Llorente Merino S L Lloyd C Y Lo E M Lobodzinska P Loch S Loffredo T Lohse K Lohwasser M Lokajicek J D Long R E Long I Longarini L Longo I Lopez Paz A Lopez Solis J Lorenz N Lorenzo Martinez A M Lory A Lösle X Lou X Lou A Lounis J Love P A Love J J Lozano Bahilo M Lu Y J Lu H J Lubatti C Luci F L Lucio Alves A Lucotte F Luehring I Luise L Luminari B Lund-Jensen N A Luongo M S Lutz D Lynn H Lyons R Lysak E Lytken F Lyu V Lyubushkin T Lyubushkina H Ma L L Ma Y Ma D M Mac Donell G Maccarrone C M Macdonald J C MacDonald J Machado Miguens R Madar W F Mader M Madugoda Ralalage Don N Madysa J Maeda T Maeno M Maerker V Magerl N Magini J Magro D J Mahon C Maidantchik A Maio K Maj O Majersky S Majewski Y Makida N Makovec B Malaescu Pa Malecki V P Maleev F Malek D Malito U Mallik C Malone S Maltezos S Malyukov J Mamuzic G Mancini J P Mandalia I Mandić L Manhaes de Andrade Filho I M Maniatis J Manjarres Ramos K H Mankinen A Mann A Manousos B Mansoulie I Manthos S Manzoni A Marantis G Marceca L Marchese G Marchiori M Marcisovsky L Marcoccia C Marcon M Marjanovic Z Marshall M U F Martensson S Marti-Garcia C B Martin T A Martin V J Martin B Martin Dit Latour L Martinelli M Martinez P Martinez Agullo V I Martinez Outschoorn S Martin-Haugh V S Martoiu A C Martyniuk A Marzin S R Maschek L Masetti T Mashimo R Mashinistov J Masik A L Maslennikov L Massa P Massarotti P Mastrandrea A Mastroberardino T Masubuchi D Matakias A Matic N Matsuzawa P Mättig J Maurer B Maček D A Maximov R Mazini I Maznas S M Mazza J P Mc Gowan S P Mc Kee T G McCarthy W P McCormack E F McDonald A E McDougall J A Mcfayden G Mchedlidze M A McKay K D McLean S J McMahon P C McNamara C J McNicol R A McPherson J E Mdhluli Z A Meadows S Meehan T Megy S Mehlhase A Mehta B Meirose D Melini B R Mellado Garcia J D Mellenthin M Melo F Meloni A Melzer E D Mendes Gouveia A M Mendes Jacques Da Costa H Y Meng L Meng X T Meng S Menke E Meoni S Mergelmeyer S A M Merkt C Merlassino P Mermod L Merola C Meroni G Merz O Meshkov J K R Meshreki J Metcalfe A S Mete C Meyer J-P Meyer M Michetti R P Middleton L Mijović G Mikenberg M Mikestikova M Mikuž H Mildner A Milic C D Milke D W Miller L S Miller A Milov D A Milstead A A Minaenko I A Minashvili L Mince A I Mincer B Mindur M Mineev Y Minegishi Y Mino L M Mir M Mironova T Mitani J Mitrevski V A Mitsou M Mittal O Miu A Miucci P S Miyagawa A Mizukami J U Mjörnmark T Mkrtchyan M Mlynarikova T Moa S Mobius K Mochizuki P Moder P Mogg S Mohapatra R Moles-Valls K Mönig E Monnier A Montalbano J Montejo Berlingen M Montella F Monticelli S Monzani N Morange A L Moreira De Carvalho D Moreno M Moreno Llácer C Moreno Martinez P Morettini M Morgenstern S Morgenstern D Mori M Morii M Morinaga V Morisbak A K Morley G Mornacchi A P Morris L Morvaj P Moschovakos B Moser M Mosidze T Moskalets P Moskvitina J Moss E J W Moyse S Muanza J Mueller R S P Mueller D Muenstermann G A Mullier D P Mungo J L Munoz Martinez F J Munoz Sanchez P Murin W J Murray A Murrone J M Muse M Muškinja C Mwewa A G Myagkov A A Myers G Myers J Myers M Myska B P Nachman O Nackenhorst A Nag Nag K Nagai K Nagano Y Nagasaka J L Nagle E Nagy A M Nairz Y Nakahama K Nakamura T Nakamura H Nanjo F Napolitano R F Naranjo Garcia R Narayan I Naryshkin M Naseri T Naumann G Navarro P Y Nechaeva F Nechansky T J Neep A Negri M Negrini C Nellist C Nelson M E Nelson S Nemecek M Nessi M S Neubauer F Neuhaus M Neumann R Newhouse P R Newman C W Ng Y S Ng Y W Y Ng B Ngair H D N Nguyen T Nguyen Manh E Nibigira R B Nickerson R Nicolaidou D S Nielsen J Nielsen M Niemeyer N Nikiforou V Nikolaenko I Nikolic-Audit K Nikolopoulos P Nilsson H R Nindhito A Nisati N Nishu R Nisius I Nitsche T Nitta T Nobe D L Noel Y Noguchi I Nomidis M A Nomura M Nordberg J Novak T Novak O Novgorodova R Novotny L Nozka K Ntekas E Nurse F G Oakham J Ocariz A Ochi I Ochoa J P Ochoa-Ricoux K O'Connor S Oda S Odaka S Oerdek A Ogrodnik A Oh C C Ohm H Oide R Oishi M L Ojeda H Okawa Y Okazaki M W O'Keefe Y Okumura A Olariu L F Oleiro Seabra S A Olivares Pino D Oliveira Damazio J L Oliver M J R Olsson A Olszewski J Olszowska Ö O Öncel D C O'Neil A P O'neill A Onofre P U E Onyisi H Oppen R G Oreamuno Madriz M J Oreglia G E Orellana D Orestano N Orlando R S Orr V O'Shea R Ospanov G Otero Y Garzon H Otono P S Ott G J Ottino M Ouchrif J Ouellette F Ould-Saada A Ouraou Q Ouyang M Owen R E Owen V E Ozcan N Ozturk J Pacalt H A Pacey K Pachal A Pacheco Pages C Padilla Aranda S Pagan Griso G Palacino S Palazzo S Palestini M Palka P Palni C E Pandini J G Panduro Vazquez P Pani G Panizzo L Paolozzi C Papadatos K Papageorgiou S Parajuli A Paramonov C Paraskevopoulos D Paredes Hernandez S R Paredes Saenz B Parida T H Park A J Parker M A Parker F Parodi E W Parrish J A Parsons U Parzefall L Pascual Dominguez V R Pascuzzi J M P Pasner F Pasquali E Pasqualucci S Passaggio F Pastore P Pasuwan S Pataraia J R Pater A Pathak J Patton T Pauly J Pearkes M Pedersen L Pedraza Diaz R Pedro T Peiffer S V Peleganchuk O Penc C Peng H Peng B S Peralva M M Perego A P Pereira Peixoto L Pereira Sanchez D V Perepelitsa E Perez Codina L Perini H Pernegger S Perrella A Perrevoort K Peters R F Y Peters B A Petersen T C Petersen E Petit V Petousis C Petridou F Petrucci M Pettee N E Pettersson K Petukhova A Peyaud R Pezoa L Pezzotti T Pham P W Phillips M W Phipps G Piacquadio E Pianori A Picazio R H Pickles R Piegaia D Pietreanu J E Pilcher A D Pilkington M Pinamonti J L Pinfold C Pitman Donaldson M Pitt L Pizzimento A Pizzini M-A Pleier V Plesanovs V Pleskot E Plotnikova P Podberezko R Poettgen R Poggi L Poggioli I Pogrebnyak D Pohl I Pokharel G Polesello A Poley A Policicchio R Polifka A Polini C S Pollard V Polychronakos D Ponomarenko L Pontecorvo S Popa G A Popeneciu L Portales D M Portillo Quintero S Pospisil K Potamianos I N Potrap C J Potter H Potti T Poulsen J Poveda T D Powell G Pownall M E Pozo Astigarraga A Prades Ibanez P Pralavorio M M Prapa S Prell D Price M Primavera M L Proffitt N Proklova K Prokofiev F Prokoshin S Protopopescu J Proudfoot M Przybycien D Pudzha A Puri P Puzo D Pyatiizbyantseva J Qian Y Qin A Quadt M Queitsch-Maitland G Rabanal Bolanos M Racko F Ragusa G Rahal J A Raine S Rajagopalan A Ramirez Morales K Ran D F Rassloff D M Rauch F Rauscher S Rave B Ravina I Ravinovich J H Rawling M Raymond A L Read N P Readioff M Reale D M Rebuzzi G Redlinger K Reeves D Reikher A Reiss A Rej C Rembser A Renardi M Renda M B Rendel A G Rennie S Resconi E D Resseguie S Rettie B Reynolds E Reynolds O L Rezanova P Reznicek E Ricci R Richter S Richter E Richter-Was M Ridel P Rieck O Rifki M Rijssenbeek A Rimoldi M Rimoldi L Rinaldi T T Rinn G Ripellino I Riu P Rivadeneira J C Rivera Vergara F Rizatdinova E Rizvi C Rizzi S H Robertson M Robin D Robinson C M Robles Gajardo M Robles Manzano A Robson A Rocchi C Roda S Rodriguez Bosca A Rodriguez Rodriguez A M Rodríguez Vera S Roe J Roggel O Røhne R Röhrig R A Rojas B Roland C P A Roland J Roloff A Romaniouk M Romano N Rompotis M Ronzani L Roos S Rosati G Rosin B J Rosser E Rossi E Rossi E Rossi L P Rossi L Rossini R Rosten M Rotaru B Rottler D Rousseau G Rovelli A Roy D Roy A Rozanov Y Rozen X Ruan T A Ruggeri F Rühr A Ruiz-Martinez A Rummler Z Rurikova N A Rusakovich H L Russell L Rustige J P Rutherfoord E M Rüttinger M Rybar G Rybkin E B Rye A Ryzhov J A Sabater Iglesias P Sabatini L Sabetta S Sacerdoti H F-W Sadrozinski R Sadykov F Safai Tehrani B Safarzadeh Samani M Safdari P Saha S Saha M Sahinsoy A Sahu M Saimpert M Saito T Saito H Sakamoto D Salamani G Salamanna A Salnikov J Salt A Salvador Salas D Salvatore F Salvatore A Salvucci A Salzburger J Samarati D Sammel D Sampsonidis D Sampsonidou J Sánchez A Sanchez Pineda H Sandaker C O Sander I G Sanderswood M Sandhoff C Sandoval D P C Sankey M Sannino Y Sano A Sansoni C Santoni H Santos S N Santpur A Santra K A Saoucha A Sapronov J G Saraiva O Sasaki K Sato F Sauerburger E Sauvan P Savard R Sawada C Sawyer L Sawyer I Sayago Galvan C Sbarra A Sbrizzi T Scanlon J Schaarschmidt P Schacht D Schaefer L Schaefer U Schäfer A C Schaffer D Schaile R D Schamberger E Schanet C Scharf N Scharmberg V A Schegelsky D Scheirich F Schenck M Schernau C Schiavi L K Schildgen Z M Schillaci E J Schioppa M Schioppa K E Schleicher S Schlenker K R Schmidt-Sommerfeld K Schmieden C Schmitt S Schmitt L Schoeffel A Schoening P G Scholer E Schopf M Schott J F P Schouwenberg J Schovancova S Schramm F Schroeder A Schulte H-C Schultz-Coulon M Schumacher B A Schumm Ph Schune A Schwartzman T A Schwarz Ph Schwemling R Schwienhorst A Sciandra G Sciolla F Scuri F Scutti L M Scyboz C D Sebastiani K Sedlaczek P Seema S C Seidel A Seiden B D Seidlitz T Seiss C Seitz J M Seixas G Sekhniaidze S J Sekula N Semprini-Cesari S Sen C Serfon L Serin L Serkin M Sessa H Severini S Sevova F Sforza A Sfyrla E Shabalina J D Shahinian N W Shaikh D Shaked Renous L Y Shan M Shapiro A Sharma A S Sharma P B Shatalov K Shaw S M Shaw M Shehade Y Shen A D Sherman P Sherwood L Shi C O Shimmin Y Shimogama M Shimojima J D Shinner I P J Shipsey S Shirabe M Shiyakova J Shlomi A Shmeleva M J Shochet J Shojaii D R Shope S Shrestha E M Shrif M J Shroff E Shulga P Sicho A M Sickles E Sideras Haddad O Sidiropoulou A Sidoti F Siegert Dj Sijacki M Silva M V Silva Oliveira S B Silverstein S Simion R Simoniello C J Simpson-Allsop S Simsek P Sinervo V Sinetckii S Singh S Sinha M Sioli I Siral S Yu Sivoklokov J Sjölin A Skaf E Skorda P Skubic M Slawinska K Sliwa V Smakhtin B H Smart J Smiesko N Smirnov S Yu Smirnov Y Smirnov L N Smirnova O Smirnova E A Smith H A Smith M Smizanska K Smolek A Smykiewicz A A Snesarev H L Snoek I M Snyder S Snyder R Sobie A Soffer A Søgaard F Sohns C A Solans Sanchez E Yu Soldatov U Soldevila A A Solodkov A Soloshenko O V Solovyanov V Solovyev P Sommer H Son A Sonay W Song W Y Song A Sopczak A L Sopio F Sopkova S Sottocornola R Soualah A M Soukharev D South S Spagnolo M Spalla M Spangenberg F Spanò D Sperlich T M Spieker G Spigo M Spina D P Spiteri M Spousta A Stabile B L Stamas R Stamen M Stamenkovic A Stampekis E Stanecka B Stanislaus M M Stanitzki M Stankaityte B Stapf E A Starchenko G H Stark J Stark P Staroba P Starovoitov S Stärz R Staszewski G Stavropoulos M Stegler P Steinberg A L Steinhebel B Stelzer H J Stelzer O Stelzer-Chilton H Stenzel T J Stevenson G A Stewart M C Stockton G Stoicea M Stolarski S Stonjek A Straessner J Strandberg S Strandberg M Strauss T Strebler P Strizenec R Ströhmer D M Strom R Stroynowski A Strubig S A Stucci B Stugu J Stupak N A Styles D Su W Su X Su N B Suarez V V Sulin M J Sullivan D M S Sultan S Sultansoy T Sumida S Sun X Sun C J E Suster M R Sutton S Suzuki M Svatos M Swiatlowski S P Swift T Swirski A Sydorenko I Sykora M Sykora T Sykora D Ta K Tackmann J Taenzer A Taffard R Tafirout E Tagiev R H M Taibah R Takashima K Takeda T Takeshita E P Takeva Y Takubo M Talby A A Talyshev K C Tam N M Tamir J Tanaka R Tanaka S Tapia Araya S Tapprogge A Tarek Abouelfadl Mohamed S Tarem K Tariq G Tarna G F Tartarelli P Tas M Tasevsky E Tassi G Tateno A Tavares Delgado Y Tayalati A J Taylor G N Taylor W Taylor H Teagle A S Tee R Teixeira De Lima P Teixeira-Dias H Ten Kate J J Teoh K Terashi J Terron S Terzo M Testa R J Teuscher N Themistokleous T Theveneaux-Pelzer D W Thomas J P Thomas E A Thompson P D Thompson E Thomson E J Thorpe V O Tikhomirov Yu A Tikhonov S Timoshenko P Tipton S Tisserant K Todome S Todorova-Nova S Todt J Tojo S Tokár K Tokushuku E Tolley R Tombs K G Tomiwa M Tomoto L Tompkins P Tornambe E Torrence H Torres E Torró Pastor M Toscani C Tosciri J Toth D R Tovey A Traeet C J Treado T Trefzger F Tresoldi A Tricoli I M Trigger S Trincaz-Duvoid D A Trischuk W Trischuk B Trocmé A Trofymov C Troncon F Trovato L Truong M Trzebinski A Trzupek F Tsai P V Tsiareshka A Tsirigotis V Tsiskaridze E G Tskhadadze M Tsopoulou I I Tsukerman V Tsulaia S Tsuno D Tsybychev Y Tu A Tudorache V Tudorache A N Tuna S Turchikhin D Turgeman I Turk Cakir R J Turner R Turra P M Tuts S Tzamarias E Tzovara K Uchida F Ukegawa G Unal M Unal A Undrus G Unel F C Ungaro Y Unno K Uno J Urban P Urquijo G Usai Z Uysal V Vacek B Vachon K O H Vadla T Vafeiadis A Vaidya C Valderanis E Valdes Santurio M Valente S Valentinetti A Valero L Valéry R A Vallance A Vallier J A Valls Ferrer T R Van Daalen P Van Gemmeren S Van Stroud I Van Vulpen M Vanadia W Vandelli M Vandenbroucke E R Vandewall D Vannicola R Vari E W Varnes C Varni T Varol D Varouchas K E Varvell M E Vasile G A Vasquez F Vazeille D Vazquez Furelos T Vazquez Schroeder J Veatch V Vecchio M J Veen L M Veloce F Veloso S Veneziano A Ventura A Verbytskyi V Vercesi M Verducci C M Vergel Infante C Vergis W Verkerke A T Vermeulen J C Vermeulen C Vernieri P J Verschuuren M C Vetterli N Viaux Maira T Vickey O E Vickey Boeriu G H A Viehhauser L Vigani M Villa M Villaplana Perez E M Villhauer E Vilucchi M G Vincter G S Virdee A Vishwakarma C Vittori I Vivarelli M Vogel P Vokac J Von Ahnen S E von Buddenbrock E Von Toerne V Vorobel K Vorobev M Vos J H Vossebeld M Vozak N Vranjes M Vranjes Milosavljevic V Vrba M Vreeswijk N K Vu R Vuillermet I Vukotic S Wada P Wagner W Wagner J Wagner-Kuhr S Wahdan H Wahlberg R Wakasa V M Walbrecht J Walder R Walker S D Walker W Walkowiak V Wallangen A M Wang A Z Wang C Wang C Wang H Wang H Wang J Wang P Wang Q Wang R-J Wang R Wang R Wang S M Wang W T Wang W Wang W X Wang Y Wang Z Wang C Wanotayaroj A Warburton C P Ward R J Ward N Warrack A T Watson M F Watson G Watts B M Waugh A F Webb C Weber M S Weber S A Weber S M Weber Y Wei A R Weidberg J Weingarten M Weirich C Weiser P S Wells T Wenaus B Wendland T Wengler S Wenig N Wermes M Wessels T D Weston K Whalen A M Wharton A S White A White M J White D Whiteson B W Whitmore W Wiedenmann C Wiel M Wielers N Wieseotte C Wiglesworth L A M Wiik-Fuchs H G Wilkens L J Wilkins D M Williams H H Williams S Williams S Willocq P J Windischhofer I Wingerter-Seez E Winkels F Winklmeier B T Winter M Wittgen M Wobisch A Wolf R Wölker J Wollrath M W Wolter H Wolters V W S Wong A F Wongel N L Woods S D Worm B K Wosiek K W Woźniak K Wraight S L Wu X Wu Y Wu J Wuerzinger T R Wyatt B M Wynne S Xella L Xia J Xiang X Xiao X Xie I Xiotidis D Xu H Xu H Xu L Xu R Xu T Xu W Xu Y Xu Z Xu Z Xu B Yabsley S Yacoob D P Yallup N Yamaguchi Y Yamaguchi A Yamamoto M Yamatani T Yamazaki Y Yamazaki J Yan Z Yan H J Yang H T Yang S Yang T Yang X Yang X Yang Y Yang Z Yang W-M Yao Y C Yap H Ye J Ye S Ye I Yeletskikh M R Yexley E Yigitbasi P Yin K Yorita K Yoshihara C J S Young C Young J Yu R Yuan X Yue M Zaazoua B Zabinski G Zacharis E Zaffaroni J Zahreddine A M Zaitsev T Zakareishvili N Zakharchuk S Zambito D Zanzi S V Zeißner C Zeitnitz G Zemaityte J C Zeng O Zenin T Ženiš D Zerwas M Zgubič B Zhang D F Zhang G Zhang J Zhang K Zhang L Zhang L Zhang M Zhang R Zhang S Zhang X Zhang X Zhang Y Zhang Z Zhang Z Zhang P Zhao Y Zhao Z Zhao A Zhemchugov Z Zheng D Zhong B Zhou C Zhou H Zhou M Zhou N Zhou Y Zhou C G Zhu C Zhu H L Zhu H Zhu J Zhu Y Zhu X Zhuang K Zhukov V Zhulanov D Zieminska N I Zimine S Zimmermann Z Zinonos M Ziolkowski L Živković G Zobernig A Zoccoli K Zoch T G Zorbas R Zou L Zwalinski

Phys Rev Lett 2021 Mar;126(12):121802

CERN, Geneva, Switzerland.

Several extensions of the Standard Model predict the production of dark matter particles at the LHC. An uncharted signature of dark matter particles produced in association with VV=W^{±}W^{∓} or ZZ pairs from a decay of a dark Higgs boson s is searched for using 139  fb^{-1} of pp collisions recorded by the ATLAS detector at a center-of-mass energy of 13 TeV. The s→V(qq[over ¯])V(qq[over ¯]) decays are reconstructed with a novel technique aimed at resolving the dense topology from boosted VV pairs using jets in the calorimeter and tracking information. Dark Higgs scenarios with m_{s}>160  GeV are excluded.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1103/PhysRevLett.126.121802DOI Listing
March 2021

Longitudinal Flow Decorrelations in Xe+Xe Collisions at sqrt[s_{NN}]=5.44  TeV with the ATLAS Detector.

Authors:
G Aad B Abbott D C Abbott A Abed Abud K Abeling D K Abhayasinghe S H Abidi O S AbouZeid N L Abraham H Abramowicz H Abreu Y Abulaiti B S Acharya B Achkar S Adachi L Adam C Adam Bourdarios L Adamczyk L Adamek J Adelman M Adersberger A Adiguzel S Adorni T Adye A A Affolder Y Afik C Agapopoulou M N Agaras A Aggarwal C Agheorghiesei J A Aguilar-Saavedra F Ahmadov W S Ahmed X Ai G Aielli S Akatsuka T P A Åkesson E Akilli A V Akimov K Al Khoury G L Alberghi J Albert M J Alconada Verzini S Alderweireldt M Aleksa I N Aleksandrov C Alexa T Alexopoulos A Alfonsi F Alfonsi M Alhroob B Ali M Aliev G Alimonti C Allaire B M M Allbrooke B W Allen P P Allport A Aloisio F Alonso C Alpigiani A A Alshehri E Alunno Camelia M Alvarez Estevez M G Alviggi Y Amaral Coutinho A Ambler L Ambroz C Amelung D Amidei S P Amor Dos Santos S Amoroso C S Amrouche F An C Anastopoulos N Andari T Andeen C F Anders J K Anders S Y Andrean A Andreazza V Andrei C R Anelli S Angelidakis A Angerami A V Anisenkov A Annovi C Antel M T Anthony E Antipov M Antonelli D J A Antrim F Anulli M Aoki J A Aparisi Pozo M A Aparo L Aperio Bella J P Araque V Araujo Ferraz R Araujo Pereira C Arcangeletti A T H Arce F A Arduh J-F Arguin S Argyropoulos J-H Arling A J Armbruster A Armstrong O Arnaez H Arnold Z P Arrubarrena Tame G Artoni S Artz S Asai T Asawatavonvanich N Asbah E M Asimakopoulou L Asquith J Assahsah K Assamagan R Astalos R J Atkin M Atkinson N B Atlay H Atmani K Augsten G Avolio M K Ayoub G Azuelos H Bachacou K Bachas M Backes F Backman P Bagnaia M Bahmani H Bahrasemani A J Bailey V R Bailey J T Baines C Bakalis O K Baker P J Bakker D Bakshi Gupta S Balaji E M Baldin P Balek F Balli W K Balunas J Balz E Banas M Bandieramonte A Bandyopadhyay Sw Banerjee L Barak W M Barbe E L Barberio D Barberis M Barbero G Barbour T Barillari M-S Barisits J Barkeloo T Barklow R Barnea B M Barnett R M Barnett Z Barnovska-Blenessy A Baroncelli G Barone A J Barr L Barranco Navarro F Barreiro J Barreiro Guimarães da Costa S Barsov F Bartels R Bartoldus G Bartolini A E Barton P Bartos A Basalaev A Basan A Bassalat M J Basso R L Bates S Batlamous J R Batley B Batool M Battaglia M Bauce F Bauer K T Bauer H S Bawa J B Beacham T Beau P H Beauchemin F Becherer P Bechtle H C Beck H P Beck K Becker C Becot A Beddall A J Beddall V A Bednyakov M Bedognetti C P Bee T A Beermann M Begalli M Begel A Behera J K Behr F Beisiegel A S Bell G Bella L Bellagamba A Bellerive P Bellos K Beloborodov K Belotskiy N L Belyaev D Benchekroun N Benekos Y Benhammou D P Benjamin M Benoit J R Bensinger S Bentvelsen L Beresford M Beretta D Berge E Bergeaas Kuutmann N Berger B Bergmann L J Bergsten J Beringer S Berlendis G Bernardi C Bernius F U Bernlochner T Berry P Berta C Bertella I A Bertram O Bessidskaia Bylund N Besson A Bethani S Bethke A Betti A J Bevan J Beyer D S Bhattacharya P Bhattarai R Bi R M Bianchi O Biebel D Biedermann R Bielski K Bierwagen N V Biesuz M Biglietti T R V Billoud M Bindi A Bingul C Bini S Biondi M Birman T Bisanz J P Biswal D Biswas A Bitadze C Bittrich K Bjørke T Blazek I Bloch C Blocker A Blue U Blumenschein G J Bobbink V S Bobrovnikov S S Bocchetta A Bocci D Bogavac A G Bogdanchikov C Bohm V Boisvert P Bokan T Bold A E Bolz M Bomben M Bona J S Bonilla M Boonekamp C D Booth H M Borecka-Bielska L S Borgna A Borisov G Borissov J Bortfeldt D Bortoletto D Boscherini M Bosman J D Bossio Sola K Bouaouda J Boudreau E V Bouhova-Thacker D Boumediene S K Boutle A Boveia J Boyd D Boye I R Boyko A J Bozson J Bracinik N Brahimi G Brandt O Brandt F Braren B Brau J E Brau W D Breaden Madden K Brendlinger L Brenner R Brenner S Bressler B Brickwedde D L Briglin D Britton D Britzger I Brock R Brock G Brooijmans W K Brooks E Brost J H Broughton P A Bruckman de Renstrom D Bruncko A Bruni G Bruni L S Bruni S Bruno M Bruschi N Bruscino L Bryngemark T Buanes Q Buat P Buchholz A G Buckley I A Budagov M K Bugge F Bührer O Bulekov T J Burch S Burdin C D Burgard A M Burger B Burghgrave J T P Burr C D Burton J C Burzynski V Büscher E Buschmann P J Bussey J M Butler C M Buttar J M Butterworth P Butti W Buttinger C J Buxo Vazquez A Buzatu A R Buzykaev G Cabras S Cabrera Urbán D Caforio H Cai V M M Cairo O Cakir N Calace P Calafiura G Calderini P Calfayan G Callea L P Caloba A Caltabiano S Calvente Lopez D Calvet S Calvet T P Calvet M Calvetti R Camacho Toro S Camarda D Camarero Munoz P Camarri D Cameron C Camincher S Campana M Campanelli A Camplani A Campoverde V Canale A Canesse M Cano Bret J Cantero T Cao Y Cao M D M Capeans Garrido M Capua R Cardarelli F Cardillo G Carducci I Carli T Carli G Carlino B T Carlson E M Carlson L Carminati R M D Carney S Caron E Carquin S Carrá J W S Carter M P Casado A F Casha F L Castillo L Castillo Garcia V Castillo Gimenez N F Castro A Catinaccio J R Catmore A Cattai V Cavaliere E Cavallaro M Cavalli-Sforza V Cavasinni E Celebi L Cerda Alberich K Cerny A S Cerqueira A Cerri L Cerrito F Cerutti A Cervelli S A Cetin Z Chadi D Chakraborty J Chan W S Chan W Y Chan J D Chapman B Chargeishvili D G Charlton T P Charman C C Chau S Che S Chekanov S V Chekulaev G A Chelkov B Chen C Chen C H Chen H Chen J Chen J Chen J Chen S Chen S J Chen X Chen Y-H Chen H C Cheng H J Cheng A Cheplakov E Cheremushkina R Cherkaoui El Moursli E Cheu K Cheung T J A Chevalérias L Chevalier V Chiarella G Chiarelli G Chiodini A S Chisholm A Chitan I Chiu Y H Chiu M V Chizhov K Choi A R Chomont S Chouridou Y S Chow M C Chu X Chu J Chudoba J J Chwastowski L Chytka D Cieri K M Ciesla D Cinca V Cindro I A Cioară A Ciocio F Cirotto Z H Citron M Citterio D A Ciubotaru B M Ciungu A Clark M R Clark P J Clark C Clement Y Coadou M Cobal A Coccaro J Cochran R Coelho Lopes De Sa H Cohen A E C Coimbra B Cole A P Colijn J Collot P Conde Muiño S H Connell I A Connelly S Constantinescu F Conventi A M Cooper-Sarkar F Cormier K J R Cormier L D Corpe M Corradi E E Corrigan F Corriveau M J Costa F Costanza D Costanzo G Cowan J W Cowley J Crane K Cranmer S J Crawley R A Creager S Crépé-Renaudin F Crescioli M Cristinziani V Croft G Crosetti A Cueto T Cuhadar Donszelmann A R Cukierman W R Cunningham S Czekierda P Czodrowski M M Czurylo M J Da Cunha Sargedas De Sousa J V Da Fonseca Pinto C Da Via W Dabrowski F Dachs T Dado S Dahbi T Dai C Dallapiccola M Dam G D'amen V D'Amico J Damp J R Dandoy M F Daneri N S Dann M Danninger V Dao G Darbo O Dartsi A Dattagupta T Daubney S D'Auria C David T Davidek D R Davis I Dawson K De R De Asmundis M De Beurs S De Castro S De Cecco N De Groot P de Jong H De la Torre A De Maria D De Pedis A De Salvo U De Sanctis M De Santis A De Santo K De Vasconcelos Corga J B De Vivie De Regie C Debenedetti D V Dedovich A M Deiana J Del Peso Y Delabat Diaz D Delgove F Deliot C M Delitzsch M Della Pietra D Della Volpe A Dell'Acqua L Dell'Asta M Delmastro C Delporte P A Delsart D A DeMarco S Demers M Demichev G Demontigny S P Denisov L D'Eramo D Derendarz J E Derkaoui F Derue P Dervan K Desch C Deterre K Dette C Deutsch M R Devesa P O Deviveiros F A Di Bello A Di Ciaccio L Di Ciaccio W K Di Clemente C Di Donato A Di Girolamo G Di Gregorio B Di Micco R Di Nardo K F Di Petrillo R Di Sipio C Diaconu F A Dias T Dias Do Vale M A Diaz J Dickinson E B Diehl J Dietrich S Díez Cornell A Dimitrievska W Ding J Dingfelder F Dittus F Djama T Djobava J I Djuvsland M A B Do Vale M Dobre D Dodsworth C Doglioni J Dolejsi Z Dolezal M Donadelli B Dong J Donini A D'onofrio M D'Onofrio J Dopke A Doria M T Dova A T Doyle E Drechsler E Dreyer T Dreyer A S Drobac D Du Y Duan F Dubinin M Dubovsky A Dubreuil E Duchovni G Duckeck A Ducourthial O A Ducu D Duda A Dudarev A C Dudder E M Duffield L Duflot M Dührssen C Dülsen M Dumancic A E Dumitriu A K Duncan M Dunford A Duperrin H Duran Yildiz M Düren A Durglishvili D Duschinger B Dutta D Duvnjak G I Dyckes M Dyndal S Dysch B S Dziedzic K M Ecker M G Eggleston T Eifert G Eigen K Einsweiler T Ekelof H El Jarrari R El Kosseifi V Ellajosyula M Ellert F Ellinghaus A A Elliot N Ellis J Elmsheuser M Elsing D Emeliyanov A Emerman Y Enari M B Epland J Erdmann A Ereditato P A Erland M Errenst M Escalier C Escobar O Estrada Pastor E Etzion H Evans M O Evans A Ezhilov F Fabbri L Fabbri V Fabiani G Facini R M Faisca Rodrigues Pereira R M Fakhrutdinov S Falciano P J Falke S Falke J Faltova Y Fang Y Fang G Fanourakis M Fanti M Faraj A Farbin A Farilla E M Farina T Farooque S M Farrington P Farthouat F Fassi P Fassnacht D Fassouliotis M Faucci Giannelli W J Fawcett L Fayard O L Fedin W Fedorko A Fehr M Feickert L Feligioni A Fell C Feng M Feng M J Fenton A B Fenyuk S W Ferguson J Ferrando A Ferrante A Ferrari P Ferrari R Ferrari D E Ferreira de Lima A Ferrer D Ferrere C Ferretti F Fiedler A Filipčič F Filthaut K D Finelli M C N Fiolhais L Fiorini F Fischer W C Fisher I Fleck P Fleischmann T Flick B M Flierl L Flores L R Flores Castillo F M Follega N Fomin J H Foo G T Forcolin A Formica F A Förster A C Forti A G Foster M G Foti D Fournier H Fox P Francavilla S Francescato M Franchini S Franchino D Francis L Franconi M Franklin A N Fray P M Freeman B Freund W S Freund E M Freundlich D C Frizzell D Froidevaux J A Frost C Fukunaga E Fullana Torregrosa T Fusayasu J Fuster A Gabrielli A Gabrielli S Gadatsch P Gadow G Gagliardi L G Gagnon B Galhardo G E Gallardo E J Gallas B J Gallop G Galster R Gamboa Goni K K Gan S Ganguly J Gao Y Gao Y S Gao C García J E García Navarro J A García Pascual C Garcia-Argos M Garcia-Sciveres R W Gardner N Garelli S Gargiulo C A Garner V Garonne S J Gasiorowski P Gaspar A Gaudiello G Gaudio I L Gavrilenko A Gavrilyuk C Gay G Gaycken E N Gazis A A Geanta C M Gee C N P Gee J Geisen M Geisen C Gemme M H Genest C Geng S Gentile S George T Geralis L O Gerlach P Gessinger-Befurt G Gessner S Ghasemi M Ghasemi Bostanabad M Ghneimat A Ghosh A Ghosh B Giacobbe S Giagu N Giangiacomi P Giannetti A Giannini G Giannini S M Gibson M Gignac D Gillberg G Gilles D M Gingrich M P Giordani P F Giraud G Giugliarelli D Giugni F Giuli S Gkaitatzis I Gkialas E L Gkougkousis P Gkountoumis L K Gladilin C Glasman J Glatzer P C F Glaysher A Glazov G R Gledhill I Gnesi M Goblirsch-Kolb D Godin S Goldfarb T Golling D Golubkov A Gomes R Goncalves Gama R Gonçalo G Gonella L Gonella A Gongadze F Gonnella J L Gonski S González de la Hoz S Gonzalez Fernandez C Gonzalez Renteria S Gonzalez-Sevilla G R Gonzalvo Rodriguez L Goossens N A Gorasia P A Gorbounov H A Gordon B Gorini E Gorini A Gorišek A T Goshaw M I Gostkin C A Gottardo M Gouighri A G Goussiou N Govender C Goy E Gozani I Grabowska-Bold E C Graham J Gramling E Gramstad S Grancagnolo M Grandi V Gratchev P M Gravila F G Gravili C Gray H M Gray C Grefe K Gregersen I M Gregor P Grenier K Grevtsov C Grieco N A Grieser A A Grillo K Grimm S Grinstein J-F Grivaz S Groh E Gross J Grosse-Knetter Z J Grout C Grud A Grummer L Guan W Guan C Gubbels J Guenther A Guerguichon J G R Guerrero Rojas F Guescini D Guest R Gugel T Guillemin S Guindon U Gul J Guo W Guo Y Guo Z Guo R Gupta S Gurbuz G Gustavino M Guth P Gutierrez C Gutschow C Guyot C Gwenlan C B Gwilliam A Haas C Haber H K Hadavand A Hadef M Haleem J Haley G Halladjian G D Hallewell K Hamacher P Hamal K Hamano H Hamdaoui M Hamer G N Hamity K Han L Han S Han Y F Han K Hanagaki M Hance D M Handl B Haney R Hankache E Hansen J B Hansen J D Hansen M C Hansen P H Hansen E C Hanson K Hara T Harenberg S Harkusha P F Harrison N M Hartman N M Hartmann Y Hasegawa A Hasib S Hassani S Haug R Hauser L B Havener M Havranek C M Hawkes R J Hawkings D Hayden C Hayes R L Hayes C P Hays J M Hays H S Hayward S J Haywood F He M P Heath V Hedberg S Heer K K Heidegger W D Heidorn J Heilman S Heim T Heim B Heinemann J J Heinrich L Heinrich J Hejbal L Helary A Held S Hellesund C M Helling S Hellman C Helsens R C W Henderson Y Heng L Henkelmann A M Henriques Correia H Herde Y Hernández Jiménez H Herr M G Herrmann T Herrmann G Herten R Hertenberger L Hervas T C Herwig G G Hesketh N P Hessey H Hibi A Higashida S Higashino E Higón-Rodriguez K Hildebrand J C Hill K K Hill K H Hiller S J Hillier M Hils I Hinchliffe F Hinterkeuser M Hirose S Hirose D Hirschbuehl B Hiti O Hladik D R Hlaluku J Hobbs N Hod M C Hodgkinson A Hoecker D Hohn D Hohov T Holm T R Holmes M Holzbock L B A H Hommels S Honda T M Hong J C Honig A Hönle B H Hooberman W H Hopkins Y Horii P Horn L A Horyn S Hou A Hoummada J Howarth J Hoya M Hrabovsky J Hrdinka I Hristova J Hrivnac A Hrynevich T Hryn'ova P J Hsu S-C Hsu Q Hu S Hu Y F Hu D P Huang Y Huang Y Huang Z Hubacek F Hubaut M Huebner F Huegging T B Huffman M Huhtinen R F H Hunter P Huo N Huseynov J Huston J Huth R Hyneman S Hyrych G Iacobucci G Iakovidis I Ibragimov L Iconomidou-Fayard P Iengo R Ignazzi O Igonkina R Iguchi T Iizawa Y Ikegami M Ikeno D Iliadis N Ilic F Iltzsche G Introzzi M Iodice K Iordanidou V Ippolito M F Isacson M Ishino W Islam C Issever S Istin F Ito J M Iturbe Ponce R Iuppa A Ivina H Iwasaki J M Izen V Izzo P Jacka P Jackson R M Jacobs B P Jaeger V Jain G Jäkel K B Jakobi K Jakobs T Jakoubek J Jamieson K W Janas R Jansky M Janus P A Janus G Jarlskog A E Jaspan N Javadov T Javůrek M Javurkova F Jeanneau L Jeanty J Jejelava A Jelinskas P Jenni N Jeong S Jézéquel H Ji J Jia H Jiang Y Jiang Z Jiang S Jiggins F A Jimenez Morales J Jimenez Pena S Jin A Jinaru O Jinnouchi H Jivan P Johansson K A Johns C A Johnson R W L Jones S D Jones S Jones T J Jones J Jongmanns P M Jorge J Jovicevic X Ju J J Junggeburth A Juste Rozas A Kaczmarska M Kado H Kagan M Kagan A Kahn C Kahra T Kaji E Kajomovitz C W Kalderon A Kaluza A Kamenshchikov M Kaneda N J Kang S Kang Y Kano J Kanzaki L S Kaplan D Kar K Karava M J Kareem I Karkanias S N Karpov Z M Karpova V Kartvelishvili A N Karyukhin A Kastanas C Kato J Katzy K Kawade K Kawagoe T Kawaguchi T Kawamoto G Kawamura E F Kay V F Kazanin R Keeler R Kehoe J S Keller E Kellermann D Kelsey J J Kempster J Kendrick K E Kennedy O Kepka S Kersten B P Kerševan S Ketabchi Haghighat M Khader F Khalil-Zada M Khandoga A Khanov A G Kharlamov T Kharlamova E E Khoda A Khodinov T J Khoo E Khramov J Khubua S Kido M Kiehn C R Kilby E Kim Y K Kim N Kimura O M Kind B T King D Kirchmeier J Kirk A E Kiryunin T Kishimoto D P Kisliuk V Kitali O Kivernyk T Klapdor-Kleingrothaus M Klassen C Klein M H Klein M Klein U Klein K Kleinknecht P Klimek A Klimentov T Klingl T Klioutchnikova F F Klitzner P Kluit S Kluth E Kneringer E B F G Knoops A Knue D Kobayashi T Kobayashi M Kobel M Kocian T Kodama P Kodys D M Koeck P T Koenig T Koffas N M Köhler M Kolb I Koletsou T Komarek T Kondo K Köneke A X Y Kong A C König T Kono V Konstantinides N Konstantinidis B Konya R Kopeliansky S Koperny K Korcyl K Kordas G Koren A Korn I Korolkov E V Korolkova N Korotkova O Kortner S Kortner V V Kostyukhin A Kotsokechagia A Kotwal A Koulouris A Kourkoumeli-Charalampidi C Kourkoumelis E Kourlitis V Kouskoura A B Kowalewska R Kowalewski W Kozanecki A S Kozhin V A Kramarenko G Kramberger D Krasnopevtsev M W Krasny A Krasznahorkay D Krauss J A Kremer J Kretzschmar P Krieger F Krieter A Krishnan K Krizka K Kroeninger H Kroha J Kroll J Kroll K S Krowpman U Kruchonak H Krüger N Krumnack M C Kruse J A Krzysiak T Kubota O Kuchinskaia S Kuday D Kuechler J T Kuechler S Kuehn A Kugel T Kuhl V Kukhtin R Kukla Y Kulchitsky S Kuleshov Y P Kulinich M Kuna T Kunigo A Kupco T Kupfer O Kuprash H Kurashige L L Kurchaninov Y A Kurochkin A Kurova M G Kurth E S Kuwertz M Kuze A K Kvam J Kvita T Kwan L La Rotonda F La Ruffa C Lacasta F Lacava D P J Lack H Lacker D Lacour E Ladygin R Lafaye B Laforge T Lagouri S Lai I K Lakomiec S Lammers W Lampl C Lampoudis E Lançon U Landgraf M P J Landon M C Lanfermann V S Lang J C Lange R J Langenberg A J Lankford F Lanni K Lantzsch A Lanza A Lapertosa S Laplace J F Laporte T Lari F Lasagni Manghi M Lassnig T S Lau A Laudrain A Laurier M Lavorgna S D Lawlor M Lazzaroni B Le E Le Guirriec A Lebedev M LeBlanc T LeCompte F Ledroit-Guillon A C A Lee C A Lee G R Lee L Lee S C Lee S Lee B Lefebvre H P Lefebvre M Lefebvre C Leggett K Lehmann N Lehmann G Lehmann Miotto W A Leight A Leisos M A L Leite C E Leitgeb R Leitner D Lellouch K J C Leney T Lenz R Leone S Leone C Leonidopoulos A Leopold C Leroy R Les C G Lester M Levchenko J Levêque D Levin L J Levinson D J Lewis B Li B Li C-Q Li F Li H Li H Li J Li K Li L Li M Li Q Li Q Y Li S Li X Li Y Li Z Li Z Li Z Liang B Liberti A Liblong K Lie S Lim C Y Lin K Lin T H Lin R A Linck R E Lindley J H Lindon A L Lionti E Lipeles A Lipniacka T M Liss A Lister J D Little B Liu B X Liu H B Liu H Liu J B Liu J K K Liu K Liu M Liu P Liu Y Liu Y Liu Y L Liu Y W Liu M Livan A Lleres J Llorente Merino S L Lloyd C Y Lo E M Lobodzinska P Loch S Loffredo T Lohse K Lohwasser M Lokajicek J D Long R E Long L Longo K A Looper I Lopez Paz A Lopez Solis J Lorenz N Lorenzo Martinez A M Lory P J Lösel A Lösle X Lou X Lou A Lounis J Love P A Love J J Lozano Bahilo M Lu Y J Lu H J Lubatti C Luci A Lucotte C Luedtke F Luehring I Luise L Luminari B Lund-Jensen M S Lutz D Lynn H Lyons R Lysak E Lytken F Lyu V Lyubushkin T Lyubushkina H Ma L L Ma Y Ma G Maccarrone A Macchiolo C M Macdonald J Machado Miguens D Madaffari R Madar W F Mader M Madugoda Ralalage Don N Madysa J Maeda T Maeno M Maerker V Magerl N Magini J Magro D J Mahon C Maidantchik T Maier A Maio K Maj O Majersky S Majewski Y Makida N Makovec B Malaescu Pa Malecki V P Maleev F Malek U Mallik D Malon C Malone S Maltezos S Malyukov J Mamuzic G Mancini I Mandić L Manhaes de Andrade Filho I M Maniatis J Manjarres Ramos K H Mankinen A Mann A Manousos B Mansoulie I Manthos S Manzoni A Marantis G Marceca L Marchese G Marchiori M Marcisovsky L Marcoccia C Marcon C A Marin Tobon M Marjanovic Z Marshall M U F Martensson S Marti-Garcia C B Martin T A Martin V J Martin B Martin Dit Latour L Martinelli M Martinez V I Martinez Outschoorn S Martin-Haugh V S Martoiu A C Martyniuk A Marzin S R Maschek L Masetti T Mashimo R Mashinistov J Masik A L Maslennikov L Massa P Massarotti P Mastrandrea A Mastroberardino T Masubuchi D Matakias A Matic N Matsuzawa P Mättig J Maurer B Maček D A Maximov R Mazini I Maznas S M Mazza S P Mc Kee T G McCarthy W P McCormack E F McDonald J A Mcfayden G Mchedlidze M A McKay K D McLean S J McMahon P C McNamara C J McNicol R A McPherson J E Mdhluli Z A Meadows S Meehan T Megy S Mehlhase A Mehta T Meideck B Meirose D Melini B R Mellado Garcia J D Mellenthin M Melo F Meloni A Melzer S B Menary E D Mendes Gouveia L Meng X T Meng S Menke E Meoni S Mergelmeyer S A M Merkt C Merlassino P Mermod L Merola C Meroni G Merz O Meshkov J K R Meshreki A Messina J Metcalfe A S Mete C Meyer J-P Meyer H Meyer Zu Theenhausen F Miano M Michetti R P Middleton L Mijović G Mikenberg M Mikestikova M Mikuž H Mildner M Milesi A Milic C D Milke D W Miller A Milov D A Milstead R A Mina A A Minaenko M Miñano Moya I A Minashvili A I Mincer B Mindur M Mineev Y Minegishi L M Mir A Mirto K P Mistry T Mitani J Mitrevski V A Mitsou M Mittal O Miu A Miucci P S Miyagawa A Mizukami J U Mjörnmark T Mkrtchyan M Mlynarikova T Moa K Mochizuki P Mogg S Mohapatra R Moles-Valls M C Mondragon K Mönig J Monk E Monnier A Montalbano J Montejo Berlingen M Montella F Monticelli S Monzani N Morange D Moreno M Moreno Llácer C Moreno Martinez P Morettini M Morgenstern S Morgenstern D Mori M Morii M Morinaga V Morisbak A K Morley G Mornacchi A P Morris L Morvaj P Moschovakos B Moser M Mosidze T Moskalets H J Moss J Moss E J W Moyse S Muanza J Mueller R S P Mueller D Muenstermann G A Mullier D P Mungo J L Munoz Martinez F J Munoz Sanchez P Murin W J Murray A Murrone M Muškinja C Mwewa A G Myagkov A A Myers J Myers M Myska B P Nachman O Nackenhorst A Nag Nag K Nagai K Nagano Y Nagasaka J L Nagle E Nagy A M Nairz Y Nakahama K Nakamura T Nakamura H Nanjo F Napolitano R F Naranjo Garcia R Narayan I Naryshkin T Naumann G Navarro P Y Nechaeva F Nechansky T J Neep A Negri M Negrini C Nellist M E Nelson S Nemecek M Nessi M S Neubauer F Neuhaus M Neumann R Newhouse P R Newman C W Ng Y S Ng Y W Y Ng B Ngair H D N Nguyen T Nguyen Manh E Nibigira R B Nickerson R Nicolaidou D S Nielsen J Nielsen N Nikiforou V Nikolaenko I Nikolic-Audit K Nikolopoulos P Nilsson H R Nindhito Y Ninomiya A Nisati N Nishu R Nisius I Nitsche T Nitta T Nobe Y Noguchi I Nomidis M A Nomura M Nordberg T Novak O Novgorodova R Novotny L Nozka K Ntekas E Nurse F G Oakham H Oberlack J Ocariz A Ochi I Ochoa J P Ochoa-Ricoux K O'Connor S Oda S Odaka S Oerdek A Ogrodnik A Oh S H Oh C C Ohm H Oide M L Ojeda H Okawa Y Okazaki M W O'Keefe Y Okumura T Okuyama A Olariu L F Oleiro Seabra S A Olivares Pino D Oliveira Damazio J L Oliver M J R Olsson A Olszewski J Olszowska D C O'Neil A P O'neill A Onofre P U E Onyisi H Oppen M J Oreglia G E Orellana D Orestano N Orlando R S Orr V O'Shea R Ospanov G Otero Y Garzon H Otono P S Ott G J Ottino M Ouchrif J Ouellette F Ould-Saada A Ouraou Q Ouyang M Owen R E Owen V E Ozcan N Ozturk J Pacalt H A Pacey K Pachal A Pacheco Pages C Padilla Aranda S Pagan Griso M Paganini G Palacino S Palazzo S Palestini M Palka D Pallin P Palni I Panagoulias C E Pandini J G Panduro Vazquez P Pani G Panizzo L Paolozzi C Papadatos K Papageorgiou S Parajuli A Paramonov D Paredes Hernandez S R Paredes Saenz B Parida T H Park A J Parker M A Parker F Parodi E W Parrish J A Parsons U Parzefall L Pascual Dominguez V R Pascuzzi J M P Pasner F Pasquali E Pasqualucci S Passaggio F Pastore P Pasuwan S Pataraia J R Pater A Pathak J Patton T Pauly J Pearkes B Pearson M Pedersen L Pedraza Diaz R Pedro T Peiffer S V Peleganchuk O Penc H Peng B S Peralva M M Perego A P Pereira Peixoto L Pereira Sanchez D V Perepelitsa F Peri L Perini H Pernegger S Perrella A Perrevoort K Peters R F Y Peters B A Petersen T C Petersen E Petit A Petridis C Petridou F Petrucci M Pettee N E Pettersson K Petukhova A Peyaud R Pezoa L Pezzotti T Pham F H Phillips P W Phillips M W Phipps G Piacquadio E Pianori A Picazio R H Pickles R Piegaia D Pietreanu J E Pilcher A D Pilkington M Pinamonti J L Pinfold C Pitman Donaldson M Pitt L Pizzimento M-A Pleier V Pleskot E Plotnikova P Podberezko R Poettgen R Poggi L Poggioli I Pogrebnyak D Pohl I Pokharel G Polesello A Poley A Policicchio R Polifka A Polini C S Pollard V Polychronakos D Ponomarenko L Pontecorvo S Popa G A Popeneciu L Portales D M Portillo Quintero S Pospisil K Potamianos I N Potrap C J Potter H Potti T Poulsen J Poveda T D Powell G Pownall M E Pozo Astigarraga P Pralavorio S Prell D Price M Primavera S Prince M L Proffitt N Proklova K Prokofiev F Prokoshin S Protopopescu J Proudfoot M Przybycien D Pudzha A Puri P Puzo J Qian Y Qin A Quadt M Queitsch-Maitland A Qureshi M Racko F Ragusa G Rahal J A Raine S Rajagopalan A Ramirez Morales K Ran T Rashid S Raspopov D M Rauch F Rauscher S Rave B Ravina I Ravinovich J H Rawling M Raymond A L Read N P Readioff M Reale D M Rebuzzi G Redlinger K Reeves L Rehnisch J Reichert D Reikher A Reiss A Rej C Rembser A Renardi M Renda M Rescigno S Resconi E D Resseguie S Rettie B Reynolds E Reynolds O L Rezanova P Reznicek E Ricci R Richter S Richter E Richter-Was O Ricken M Ridel P Rieck O Rifki M Rijssenbeek A Rimoldi M Rimoldi L Rinaldi G Ripellino I Riu J C Rivera Vergara F Rizatdinova E Rizvi C Rizzi R T Roberts S H Robertson M Robin D Robinson C M Robles Gajardo M Robles Manzano A Robson A Rocchi E Rocco C Roda S Rodriguez Bosca A Rodriguez Perez D Rodriguez Rodriguez A M Rodríguez Vera S Roe O Røhne R Röhrig R A Rojas B Roland C P A Roland J Roloff A Romaniouk M Romano N Rompotis M Ronzani L Roos S Rosati G Rosin B J Rosser E Rossi E Rossi E Rossi L P Rossi L Rossini R Rosten M Rotaru B Rottler D Rousseau G Rovelli A Roy D Roy A Rozanov Y Rozen X Ruan F Rühr A Ruiz-Martinez A Rummler Z Rurikova N A Rusakovich H L Russell L Rustige J P Rutherfoord E M Rüttinger M Rybar G Rybkin E B Rye A Ryzhov J A Sabater Iglesias P Sabatini S Sacerdoti H F-W Sadrozinski R Sadykov F Safai Tehrani B Safarzadeh Samani M Safdari P Saha S Saha M Sahinsoy A Sahu M Saimpert M Saito T Saito H Sakamoto D Salamani G Salamanna J E Salazar Loyola A Salnikov J Salt A Salvador Salas D Salvatore F Salvatore A Salvucci A Salzburger J Samarati D Sammel D Sampsonidis D Sampsonidou J Sánchez A Sanchez Pineda H Sandaker C O Sander I G Sanderswood M Sandhoff C Sandoval D P C Sankey M Sannino Y Sano A Sansoni C Santoni H Santos S N Santpur A Santra A Sapronov J G Saraiva O Sasaki K Sato F Sauerburger E Sauvan P Savard R Sawada C Sawyer L Sawyer C Sbarra A Sbrizzi T Scanlon J Schaarschmidt P Schacht B M Schachtner D Schaefer L Schaefer J Schaeffer S Schaepe U Schäfer A C Schaffer D Schaile R D Schamberger N Scharmberg V A Schegelsky D Scheirich F Schenck M Schernau C Schiavi L K Schildgen Z M Schillaci E J Schioppa M Schioppa K E Schleicher S Schlenker K R Schmidt-Sommerfeld K Schmieden C Schmitt S Schmitt S Schmitz J C Schmoeckel L Schoeffel A Schoening P G Scholer E Schopf M Schott J F P Schouwenberg J Schovancova S Schramm F Schroeder A Schulte H-C Schultz-Coulon M Schumacher B A Schumm Ph Schune A Schwartzman T A Schwarz Ph Schwemling R Schwienhorst A Sciandra G Sciolla M Scodeggio M Scornajenghi F Scuri F Scutti L M Scyboz C D Sebastiani P Seema S C Seidel A Seiden B D Seidlitz T Seiss C Seitz J M Seixas G Sekhniaidze S J Sekula N Semprini-Cesari S Sen C Serfon L Serin L Serkin M Sessa H Severini S Sevova F Sforza A Sfyrla E Shabalina J D Shahinian N W Shaikh D Shaked Renous L Y Shan M Shapiro A Sharma A S Sharma P B Shatalov K Shaw S M Shaw M Shehade Y Shen A D Sherman P Sherwood L Shi S Shimizu C O Shimmin Y Shimogama M Shimojima I P J Shipsey S Shirabe M Shiyakova J Shlomi A Shmeleva M J Shochet J Shojaii D R Shope S Shrestha E M Shrif E Shulga P Sicho A M Sickles P E Sidebo E Sideras Haddad O Sidiropoulou A Sidoti F Siegert Dj Sijacki M Silva M V Silva Oliveira S B Silverstein S Simion R Simoniello C J Simpson-Allsop S Simsek P Sinervo V Sinetckii S Singh M Sioli I Siral S Yu Sivoklokov J Sjölin E Skorda P Skubic M Slawinska K Sliwa R Slovak V Smakhtin B H Smart J Smiesko N Smirnov S Yu Smirnov Y Smirnov L N Smirnova O Smirnova J W Smith M Smizanska K Smolek A Smykiewicz A A Snesarev H L Snoek I M Snyder S Snyder R Sobie A Soffer A Søgaard F Sohns C A Solans Sanchez E Yu Soldatov U Soldevila A A Solodkov A Soloshenko O V Solovyanov V Solovyev P Sommer H Son W Song W Y Song A Sopczak A L Sopio F Sopkova C L Sotiropoulou S Sottocornola R Soualah A M Soukharev D South S Spagnolo M Spalla M Spangenberg F Spanò D Sperlich T M Spieker G Spigo M Spina D P Spiteri M Spousta A Stabile B L Stamas R Stamen M Stamenkovic E Stanecka B Stanislaus M M Stanitzki M Stankaityte B Stapf E A Starchenko G H Stark J Stark P Staroba P Starovoitov S Stärz R Staszewski G Stavropoulos M Stegler P Steinberg A L Steinhebel B Stelzer H J Stelzer O Stelzer-Chilton H Stenzel T J Stevenson G A Stewart M C Stockton G Stoicea M Stolarski S Stonjek A Straessner J Strandberg S Strandberg M Strauss P Strizenec R Ströhmer D M Strom R Stroynowski A Strubig S A Stucci B Stugu J Stupak N A Styles D Su W Su S Suchek V V Sulin M J Sullivan D M S Sultan S Sultansoy T Sumida S Sun X Sun K Suruliz C J E Suster M R Sutton S Suzuki M Svatos M Swiatlowski S P Swift T Swirski A Sydorenko I Sykora M Sykora T Sykora D Ta K Tackmann J Taenzer A Taffard R Tafirout R Takashima K Takeda T Takeshita E P Takeva Y Takubo M Talby A A Talyshev N M Tamir J Tanaka R Tanaka S Tapia Araya S Tapprogge A Tarek Abouelfadl Mohamed S Tarem K Tariq G Tarna G F Tartarelli P Tas M Tasevsky T Tashiro E Tassi A Tavares Delgado Y Tayalati A J Taylor G N Taylor W Taylor H Teagle A S Tee R Teixeira De Lima P Teixeira-Dias H Ten Kate J J Teoh S Terada K Terashi J Terron S Terzo M Testa R J Teuscher S J Thais N Themistokleous T Theveneaux-Pelzer F Thiele D W Thomas J O Thomas J P Thomas P D Thompson L A Thomsen E Thomson E J Thorpe R E Ticse Torres V O Tikhomirov Yu A Tikhonov S Timoshenko P Tipton S Tisserant K Todome S Todorova-Nova S Todt J Tojo S Tokár K Tokushuku E Tolley K G Tomiwa M Tomoto L Tompkins P Tornambe E Torrence H Torres E Torró Pastor C Tosciri J Toth D R Tovey A Traeet C J Treado T Trefzger F Tresoldi A Tricoli I M Trigger S Trincaz-Duvoid D A Trischuk W Trischuk B Trocmé A Trofymov C Troncon F Trovato L Truong M Trzebinski A Trzupek F Tsai J C-L Tseng P V Tsiareshka A Tsirigotis V Tsiskaridze E G Tskhadadze M Tsopoulou I I Tsukerman V Tsulaia S Tsuno D Tsybychev Y Tu A Tudorache V Tudorache T T Tulbure A N Tuna S Turchikhin D Turgeman I Turk Cakir R J Turner R Turra P M Tuts S Tzamarias E Tzovara G Ucchielli K Uchida F Ukegawa G Unal A Undrus G Unel F C Ungaro Y Unno K Uno J Urban P Urquijo G Usai Z Uysal V Vacek B Vachon K O H Vadla A Vaidya C Valderanis E Valdes Santurio M Valente S Valentinetti A Valero L Valéry R A Vallance A Vallier J A Valls Ferrer T R Van Daalen P Van Gemmeren I Van Vulpen M Vanadia W Vandelli M Vandenbroucke E R Vandewall A Vaniachine D Vannicola R Vari E W Varnes C Varni T Varol D Varouchas K E Varvell M E Vasile G A Vasquez F Vazeille D Vazquez Furelos T Vazquez Schroeder J Veatch V Vecchio M J Veen L M Veloce F Veloso S Veneziano A Ventura N Venturi A Verbytskyi V Vercesi M Verducci C M Vergel Infante C Vergis W Verkerke A T Vermeulen J C Vermeulen C Vernieri M C Vetterli N Viaux Maira T Vickey O E Vickey Boeriu G H A Viehhauser L Vigani M Villa M Villaplana Perez E Vilucchi M G Vincter G S Virdee A Vishwakarma C Vittori I Vivarelli M Vogel P Vokac S E von Buddenbrock E Von Toerne V Vorobel K Vorobev M Vos J H Vossebeld M Vozak N Vranjes M Vranjes Milosavljevic V Vrba M Vreeswijk R Vuillermet I Vukotic S Wada P Wagner W Wagner J Wagner-Kuhr S Wahdan H Wahlberg R Wakasa V M Walbrecht J Walder R Walker S D Walker W Walkowiak V Wallangen A M Wang A Z Wang C Wang F Wang H Wang H Wang J Wang J Wang P Wang Q Wang R-J Wang R Wang R Wang S M Wang W T Wang W Wang W X Wang Y Wang Z Wang C Wanotayaroj A Warburton C P Ward D R Wardrope N Warrack A Washbrook A T Watson M F Watson G Watts B M Waugh A F Webb C Weber M S Weber S A Weber S M Weber A R Weidberg J Weingarten M Weirich C Weiser P S Wells T Wenaus T Wengler S Wenig N Wermes M D Werner M Wessels T D Weston K Whalen N L Whallon A M Wharton A S White A White M J White D Whiteson B W Whitmore W Wiedenmann C Wiel M Wielers N Wieseotte C Wiglesworth L A M Wiik-Fuchs H G Wilkens L J Wilkins H H Williams S Williams C Willis S Willocq I Wingerter-Seez E Winkels F Winklmeier B T Winter M Wittgen M Wobisch A Wolf T M H Wolf R Wolff R Wölker J Wollrath M W Wolter H Wolters V W S Wong N L Woods S D Worm B K Wosiek K W Woźniak K Wraight S L Wu X Wu Y Wu T R Wyatt B M Wynne S Xella Z Xi L Xia X Xiao I Xiotidis D Xu H Xu H Xu L Xu T Xu W Xu Z Xu Z Xu B Yabsley S Yacoob K Yajima D P Yallup N Yamaguchi Y Yamaguchi A Yamamoto M Yamatani T Yamazaki Y Yamazaki J Yan Z Yan H J Yang H T Yang S Yang T Yang X Yang Y Yang Z Yang W-M Yao Y C Yap Y Yasu E Yatsenko H Ye J Ye S Ye I Yeletskikh M R Yexley E Yigitbasi K Yorita K Yoshihara C J S Young C Young J Yu R Yuan X Yue M Zaazoua B Zabinski G Zacharis E Zaffaroni J Zahreddine A M Zaitsev T Zakareishvili N Zakharchuk S Zambito D Zanzi D R Zaripovas S V Zeißner C Zeitnitz G Zemaityte J C Zeng O Zenin T Ženiš D Zerwas M Zgubič B Zhang D F Zhang G Zhang H Zhang J Zhang K Zhang L Zhang L Zhang M Zhang R Zhang S Zhang X Zhang X Zhang Y Zhang Z Zhang Z Zhang P Zhao Z Zhao A Zhemchugov Z Zheng D Zhong B Zhou C Zhou H Zhou M S Zhou M Zhou N Zhou Y Zhou C G Zhu C Zhu H L Zhu H Zhu J Zhu Y Zhu X Zhuang K Zhukov V Zhulanov D Zieminska N I Zimine S Zimmermann Z Zinonos M Ziolkowski L Živković G Zobernig A Zoccoli K Zoch T G Zorbas R Zou L Zwalinski

Phys Rev Lett 2021 Mar;126(12):122301

CERN, Geneva, Switzerland.

The first measurement of longitudinal decorrelations of harmonic flow amplitudes v_{n} for n=2-4 in Xe+Xe collisions at sqrt[s_{NN}]=5.44  TeV is obtained using 3  μb^{-1} of data with the ATLAS detector at the LHC. The decorrelation signal for v_{3} and v_{4} is found to be nearly independent of collision centrality and transverse momentum (p_{T}) requirements on final-state particles, but for v_{2} a strong centrality and p_{T} dependence is seen. When compared with the results from Pb+Pb collisions at sqrt[s_{NN}]=5.02  TeV, the longitudinal decorrelation signal in midcentral Xe+Xe collisions is found to be larger for v_{2}, but smaller for v_{3}. Current hydrodynamic models reproduce the ratios of the v_{n} measured in Xe+Xe collisions to those in Pb+Pb collisions but fail to describe the magnitudes and trends of the ratios of longitudinal flow decorrelations between Xe+Xe and Pb+Pb. The results on the system-size dependence provide new insights and an important lever arm to separate effects of the longitudinal structure of the initial state from other early and late time effects in heavy-ion collisions.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1103/PhysRevLett.126.122301DOI Listing
March 2021

Biosynthesis of Cyclophane-Containing Hirsutellone Family of Fungal Natural Products.

J Am Chem Soc 2021 Apr 9. Epub 2021 Apr 9.

State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, MOE-LSB and MOE-LSC, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.

Hirsutellones are fungal natural products containing a macrocyclic cyclophane connected to a decahydrofluorene ring system. We have elucidated the biosynthetic pathway for pyrrocidine B () and GKK1032 A (). Two small hypothetical proteins, an oxidoreductase and a lipocalin-like protein, function cooperatively in the oxidative cyclization of the cyclophane, while an additional hypothetical protein in the pyrrocidine pathway catalyzes the specific cycloaddition to form the fused decahydrofluorene.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1021/jacs.1c00098DOI Listing
April 2021

Triple-Modulated Chiral Inversion of Co-Assembly System Based on Alanine Amphiphile and Cyanostilbene Derivative.

ACS Appl Mater Interfaces 2021 Apr 9. Epub 2021 Apr 9.

State Key Laboratory of Chemical Resource Engineering, Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Laboratory of Biomedical Materials, Beijing University of Chemical Technology, Beijing 100029, P. R. China.

The construction of chiroptical materials with controllable chirality is of special importance in biology and chemistry. Although tunable chirality can be realized in various systems, it remains a fundamental challenge to realize multimodulated chiral inversion. Herein, we report that chiral alanine derivative and fluorescent cyanostilbene derivative co-assemble to prepare supramolecular chiral systems, where twist nanofibers with totally inverted supramolecular chirality and circularly polarized luminescence are obtained through stoichiometric modulation. The supramolecular handedness can be inverted by means of altering the cooling rate and incorporating metal ions. The mechanism study reveals that the synergistic effect among hydrogen bonds, coordination interactions, and π-π stacking interactions contributes to the chirality inversion. This work establishes an effective strategy to precisely modulate supramolecular chirality in multiple ways, which shows great potential in developing smart chiroptical materials capable of achieving complex functionalities.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsami.1c03940DOI Listing
April 2021

[Identification of TCF3-ZNF384 fusion by transcriptome sequencing in B cell acute lymphoblastic leukemia and its laboratory and clinical characteristics].

Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2021 Apr;38(4):351-354

Department of Pathology and Laboratory Medicine, Beijing Ludaopei Hospital, Beijing 100176, China.

Objective: To detect fusion gene with pathological significance in a patient with refractory and relapsed acute B cell lymphoblastic leukemia (B-ALL) and to explore its laboratory and clinical characteristics.

Methods: Transcriptome sequencing was used to detect potential fusion transcripts. Other laboratory results and clinical data of the patient were also analyzed.

Results: The patient was found to harbor TCF3 exon 17-ZNF384 exon 7 in-frame fusion transcript. The minimal residual disease (MRD) has remained positive after multiple chemotherapy protocols including CD19-, CD22- targeted chimeric antigen receptor T cells immunotherapy. The patient eventually achieved complete remission and sustained MRD negativity after allogeneic hemopoietic stem cell transplantation (allo-HSCT).

Conclusion: Transcriptome sequencing can effectively detect potential fusion genes with clinical significance in leukemia. TCF3-ZNF384 positive B-ALL has unique laboratory and clinical characteristics, may not well respond to chemotherapy and immunotherapy, and is more likely to relapse. Timely allo-HSCT treatment may help such patients to achieve long-term disease-free survival. TCF3-ZNF384 positive B-ALL is not uncommon in pediatric patients but has not been effectively identified.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn511374-20200416-00273DOI Listing
April 2021

Characterization of Exosomes in Plasma of Patients with Breast, Ovarian, Prostate, Hepatic, Gastric, Colon, and Pancreatic Cancers.

J Cancer Ther 2019 May 29;10(5):382-399. Epub 2019 May 29.

Guangxi Key Laboratory of Translational Medicine for Treating High-Incidence Infectious Diseases with Integrative Medicine, Guangxi University of Chinese Medicine, Nanning, Guangxi, China.

Detection of circulating tumor-specific DNA, RNA or proteins can be difficult due to relative scarcity. Exosomes are extracellular vesicles, 30 - 150 nm in diameter derived from fusion of multivesicular bodies with the plasma membrane. They are composed of a lipid bilayer membrane and contain proteins, mRNA and miRNA. Exosomes are secreted by multiple cell types, including cancer cells. However, there is a relative lack of information concerning the contents of exosomes secreted by various tumor cell types. To examine exosomes in cancer, we collected blood plasma samples from patients with breast, ovarian, prostate, hepatic, gastric, colon, and pancreatic cancers. Exosomes were isolated from plasma and confirmed by AchE assay, transmission electron microscopy and expression of the CD63 exosomal marker. Expression of AFP, CA724, CA153, CEA, CA125, CA199 and PSA antigens were determined using an automated electro-chemiluminescence assay. Expression of the tumor-related chaperone protein, mortalin, was determined by Western blot analysis. Levels of exosome secretion were variable among the different tumor types. Both exosome levels and mortalin expression within tumor cell exosomes were higher than in healthy donors, except in pancreatic carcinoma, where exosomes were elevated but mortalin expression was not significantly different from healthy donors. Exosomes provide unique opportunities for the enrichment of tumor-specific materials and may be useful as biomarkers and possibly as tools of cancer therapies. Mortalin, which has been linked to cell proliferation and induction of epithelial-mesenchymal transition of cancer cells, may be useful as a prognostic bio-marker and as a possible therapeutic target.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.4236/jct.2019.105032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025783PMC
May 2019

The Impact of Lymphopenia and Dosimetric Parameters on Overall Survival of Esophageal Cancer Patients Treated with Definitive Radiotherapy.

Cancer Manag Res 2021 30;13:2917-2924. Epub 2021 Mar 30.

Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Institute of Radiotherapy and Oncology, Soochow University, Suzhou, 215004, People's Republic of China.

Purpose: The objectives of the present study are to perform a survival analysis of patients with thoracic esophageal squamous cell carcinoma (ESCC) receiving definitive radiotherapy and to identify prognostic factors from among the hematological and dosimetric factors.

Methods: Cases of thoracic ESCC treated with radical RT between 2014 and 2017 were identified. The impact of clinicopathological factors on overall survival (OS) were analyzed using the Cox proportional hazards model. Absolute lymphocyte counts (ALC) and the neutrophil-to-lymphocyte ratio (NLR = ANC/ALC) were assessed before, during, and after radiotherapy (RT). Cox regression was used to correlate clinical factors with hematologic toxicities, dosimetric parameters and overall survival. Multiple logistic regression analysis was used to identify associations between lymphopenia and dosimetric parameters. With the overall survival status and real time events, the X-tile program was utilized to determine the optimal cut-off value of pretreatment NLR, and ALC nadir.

Results: Ninety-nine ESCC patients were enrolled in the present study. They had a median OS of 23 months. The median RT dose was 55.75Gy (46-66Gy), and the mean dose (D) of the thoracic vertebrae (TVB) was 27.04±9.65Gy. Based on the multivariate analysis, the V20 of TVB, the pretreatment NLR, and the ALC nadir were associated with significantly worse OS. Concurrent CRT, which entailed increasing the mean TVB dose and V20 of TVB, was linked to a higher probability of lymphopenia risk (P<0.05). This was ascertained through the multiple logistic regression analysis.

Conclusion: In ESCC patients who received definitive RT, V of TVB, pretreatment NLR, and ALC nadir during RT were independent prognostic factors and chemotherapy regimen, mean TVB dose, and V of TVB were associated with lymphopenia.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S297010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020450PMC
March 2021

Stratifin promotes renal dysfunction in ischemic and nephrotoxic AKI mouse models via enhancing RIPK3-mediated necroptosis.

Acta Pharmacol Sin 2021 Apr 8. Epub 2021 Apr 8.

School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, China.

Stratifin (SFN) is a member of the 14-3-3 family of highly conserved soluble acidic proteins, which regulates a variety of cellular activities such as cell cycle, cell growth and development, cell survival and death, and gene transcription. Acute kidney injury (AKI) is prevalent disorder characterized by inflammatory response, oxidative stress, and programmed cell death in renal tubular epithelial cells, but there is still a lack of effective therapeutic target for AKI. In this study, we investigated the role of SFN in AKI and the underlying mechanisms. We established ischemic and nephrotoxic AKI mouse models caused by ischemia-reperfusion (I/R) and cisplatin, respectively. We conducted proteomic and immunohistochemical analyses and found that SFN expression levels were significantly increased in AKI patients, cisplatin- or I/R-induced AKI mice. In cisplatin- or hypoxia/reoxygenation (H/R)-treated human proximal tubule epithelial cells (HK2), we showed that knockdown of SFN significantly reduced the expression of kidney injury marker Kim-1, attenuated programmed cell death and inflammatory response. Knockdown of SFN also significantly alleviated the decline of renal function and histological damage in cisplatin-caused AKI mice in vivo. We further revealed that SFN bound to RIPK3, a key signaling modulator in necroptosis, to induce necroptosis and the subsequent inflammation in cisplatin- or H/R-treated HK2 cells. Overexpression of SFN increased Kim-1 protein levels in cisplatin-treated MTEC cells, which was suppressed by RIPK3 knockout. Taken together, our results demonstrate that SFN that enhances cisplatin- or I/R-caused programmed cell death and inflammation via interacting with RIPK3 may serve as a promising therapeutic target for AKI treatment.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41401-021-00649-wDOI Listing
April 2021

Establishment of bovine expanded potential stem cells.

Proc Natl Acad Sci U S A 2021 Apr;118(15)

The State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, Inner Mongolia University, 010070 Hohhot, China;

Embryonic stem cells (ESCs) and induced pluripotent stem cells have the potential to differentiate to all cell types of an adult individual and are useful for studying development and for translational research. However, extrapolation of mouse and human ESC knowledge to deriving stable ESC lines of domestic ungulates and large livestock species has been challenging. In contrast to ESCs that are usually established from the blastocyst, mouse expanded potential stem cells (EPSCs) are derived from four-cell and eight-cell embryos. We have recently used the EPSC approach and established stem cells from porcine and human preimplantation embryos. EPSCs are molecularly similar across species and have broader developmental potential to generate embryonic and extraembryonic cell lineages. We further explore the EPSC technology for mammalian species refractory to the standard ESC approaches and report here the successful establishment of bovine EPSCs (bEPSCs) from preimplantation embryos of both wild-type and somatic cell nuclear transfer. bEPSCs express high levels of pluripotency genes, propagate robustly in feeder-free culture, and are genetically stable in long-term culture. bEPSCs have enriched transcriptomic features of early preimplantation embryos and differentiate in vitro to cells of the three somatic germ layers and, in chimeras, contribute to both the embryonic (fetal) and extraembryonic cell lineages. Importantly, precise gene editing is efficiently achieved in bEPSCs, and genetically modified bEPSCs can be used as donors in somatic cell nuclear transfer. bEPSCs therefore hold the potential to substantially advance biotechnology and agriculture.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.2018505118DOI Listing
April 2021

Comparison and clinical characteristics of COVID-19 between January and February 2020 in Wuhan, China.

Ann Palliat Med 2021 Mar 23. Epub 2021 Mar 23.

Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.

Background: Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) continues to make a deadly impact on human life all over the world. Therefore, we aimed to analyze the changes in clinical characteristics of coronavirus disease 2019 (COVID-19) patients over time.

Methods: We recruited 896 patients who were admitted to the Renmin Hospital of Wuhan University between 30th January 2020 and 16st March 2020. We conducted a retrospective study collecting clinical characteristics, radiologic and laboratory findings, treatments administered, and clinical outcomes in the patients. The data collected were compared between patients with onset of illness in January 2020 and patients with onset of illness in February 2020, in Wuhan, China. Categorical data and non-normally distributed continuous data were examined by the χ 2 test and the Mann-Whitney-Wilcoxon test respectively, and the Kaplan-Meier plot was used to analyze survival data. Univariate and multivariate logistic regression methods were used to explore the risk factors associated with in-hospital death.

Results: A total of 896 patients were enrolled; the median age was 60 (range, 47-69) years, 685 (76.5%) were categorized into group A (patients with onset of illness in January 2020), and 211 (23.5%) were categorized into group B (patients with onset of illness in February 2020). Compared with group B, group A had a higher incidence of fever (P<0.001), and a lower rate of asymptomatic individuals (P<0.001). Group A patients had a higher incidence of neutrophilia (P=0.043), an elevated D-dimer (P<0.001), and an increased lactate dehydrogenase (LDH) (P=0.002), but a lower incidence of a normal computed tomography (CT) scan (P=0.001). CD3 cell counts (P=0.015) and CD4 cell counts (P=0.04) were significantly reduced in group A patients. Critically ill patients were less frequent (P=0.005) and patients with milder disease were more common (P=0.001) in group B. The fatality rate was significantly less in group B patients (P=0.028). Multivariate regression indicated that older age (odds ratio 1.086, 95% CI: 1.061-1.111, per year increase; P<0.001) increased the risk of in-hospital death. Female sex (odds ratio 0.523, 95% CI: 0.316-0.865; P=0.012) and being in group B (odds ratio 0.423, 95% CI: 0.212-0.844; P=0.015) significantly decreased the risk of in-hospital death.

Conclusions: The condition of patients with onset of illness in January was more serious than that of patients with onset of illness in February 2020. The time of onset of illness was an independent risk factor for in-hospital death comparing January and February 2020. Changing pathogenicity of SARS-CoV-2 and improved healthcare may have contributed to the results, however, more basic research is required to support this hypothesis.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.21037/apm-20-2222DOI Listing
March 2021

Semi-grand canonical Monte Carlo simulation of the acrolein induced surface segregation and aggregation of AgPd with machine learning surrogate models.

J Chem Phys 2021 Apr;154(13):134701

Department of Chemical Engineering, Carnegie Mellon University, 5000 Forbes Ave., Pittsburgh, Pennsylvania 15213, USA.

The single atom alloy of AgPd has been found to be a promising catalyst for the selective hydrogenation of acrolein. It is also known that the formation of Pd islands on the surface will greatly reduce the selectivity of the reaction. As a result, the surface segregation and aggregation of Pd on the AgPd surface under reaction conditions of selective hydrogenation of acrolein are of great interest. In this work, we lay out a workflow that can predict the surface segregation and aggregation of Pd on a FCC(111) AgPd surface with and without the presence of acrolein. We use machine learning surrogate models to predict the AgPd bulk energy, AgPd slab energy, and acrolein adsorption energy on AgPd slabs. Then, we use the semi-grand canonical Monte Carlo simulation to predict the surface segregation and aggregation under different bulk Pd concentrations. Under vacuum conditions, our method predicts that only trace amount of Pd will exist on the surface at Pd bulk concentrations less than 20%. However, with the presence of acrolein, Pd will start to aggregate as dimers on the surface at Pd bulk concentrations as low as 6.5%.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1063/5.0046440DOI Listing
April 2021

Efficacy and safety of moxibustion for menstrual irregularities: A protocol for systematic review and meta-analysis.

Medicine (Baltimore) 2021 Apr;100(14):e25281

Jiangxi Province Hospital of Integrated Chinese and Western Medicine.

Background: Menstrual irregularities (MI) is 1 of the most common clinical gynaecological diseases, with abnormal menstrual cycles, abnormal bleeding, and abdominal pain before or during menstruation as the main clinical manifestations. In modern medicine, abnormalities in the function of the pituitary gland, hypothalamus, and ovaries can affect menstruation. Currently, hormone levels in the body are mostly regulated by hormonal drugs, but these drugs can lead to hormonal imbalance, which can lead to adverse reactions. Many clinical studies have reported that moxibustion has a good effect on MI treatment, but there is no relevant systematic review. So the purpose of this study is to evaluate the effectiveness and safety of moxibustion in treating MI.

Methods: The following 8 electronic databases will be searched, including PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, Web of Science, Chinese Scientific Journal Database, Wanfang Database, and Chinese Biomedical Literatures Database from their inception to 1 December 2020 without any restrictions. Researchers retrieve the literature and extracted the data, evaluation of research methods, quality of literature. The outcomes will include total effective rate, incidence of any adverse events. We use the Cochrane Risk of a bias assessment tool to evaluate methodological qualities. Data synthesis will be completed by RevMan 5.3.0.

Results: We will show the results of this study in a peer-reviewed journal.

Conclusions: This meta-analysis will provide reliable evidence for treatment of menstrual irregularities.

Inplasy Registration Number: INPLASY2020120042.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000025281DOI Listing
April 2021

Long Noncoding RNA NEAT1: A Potential Biomarker in the Progression of Laryngeal Squamous Cell Carcinoma.

ORL J Otorhinolaryngol Relat Spec 2021 Apr 8:1-7. Epub 2021 Apr 8.

Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated Hospital, Harbin Medical University, 150086, Harbin, China.

Introduction: Laryngeal squamous cell carcinoma (LSCC) is diverse in its natural history and responsiveness to treatments. There is an urgent need to generate candidate biomarkers for the stratification and individualization of treatment to avoid overtreatment or inadequate treatment. Long noncoding RNA nuclear paraspeckle assembly transcript 1 (NEAT1) has been identified as an oncogenic gene in multiple human tumors entitles, and dysregulation of NEAT1 was tightly linked to carcinogenesis and cancer progression.

Methods: One hundred two paraffin samples of LSCC patients were collected. Furthermore, in situ hybridization (ISH), Kaplan-Meier, and MTT were used to analyze the relationship between NEAT1 and the progress of LSCC.

Results: In this study, ISH revealed that NEAT1 was strongly expressed in the nucleus. The increased expression of NEAT1 was correlated with T grade, neck nodal metastasis, clinical stage, drinking history, or smoking history of LSCC. The Kaplan-Meier analysis indicated that patients with higher NEAT1 expression had a worse overall survival in LSCC patients. In addition, NEAT1 knockdown significantly inhibited the growth of LSCC cells.

Conclusion: Together, these results suggested that NEAT1 involved in the progress of LSCC and might act as a tumor oncogenic gene. This study provides a potential new marker and target for gene therapy in the treatment of LSCC.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1159/000515228DOI Listing
April 2021

Natural products as pharmacological modulators of mitochondrial dysfunctions for the treatments of Alzheimer's disease: A comprehensive review.

Eur J Med Chem 2021 Mar 27;218:113401. Epub 2021 Mar 27.

Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China. Electronic address:

Alzheimer's disease (AD) is the most common progressive neurodegenerative disorder characterized by neuronal loss and cognitive impairment that harshly affect the elderly individuals. Currently, the available anti-AD pharmacological approaches are purely symptomatic to alleviate AD symptoms, and the curative effects of novel anti-AD drugs focused on Aβ target are disappointing. Hence, there is a tremendous need to adjust AD therapeutic targets and discover novel anti-AD agents. In AD, mitochondrial dysfunction gradually triggers neuronal death from different aspects and worsens the occurrence and progress of AD. Consequently, it has been proposed that the intervention of impaired mitochondria represents an attractive breakthrough point for AD treatments. Due to chemical diversity, poly-pharmacological activities, few adverse effects and multiple targeting, natural products (NPs) have been identified as a valuable treasure for drug discovery and development. Multiple lines of studies have scientifically proven that NPs display ameliorative benefits in AD treatment in relation to mitochondrial dysfunction. This review surveys the complicated implications for mitochondrial dysregulation and AD, and then summarizes the potentials of NPs and their underlying molecular mechanisms against AD via reducing or improving mitochondrial dysfunction. It is expected that this work may open the window to speed up the development of innovative anti-AD drugs originated from NPs and improve upcoming AD therapeutics.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2021.113401DOI Listing
March 2021

Cardiac fibrosis: myofibroblast-mediated pathological regulation and drug delivery strategies.

Adv Drug Deliv Rev 2021 Apr 5. Epub 2021 Apr 5.

Department of Molecular Biomedical Sciences, North Carolina State University, North Carolina, USA; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, USA. Electronic address:

Cardiac fibrosis remains an unresolved problem in heart diseases. After initial injury, cardiac fibroblasts (CFs) are activated and subsequently differentiate into myofibroblasts (myoFbs) that are major mediator cells in the pathological remodeling. MyoFbs exhibit proliferative and secretive characteristics, and contribute to extracellular matrix (ECM) turnover, collagen deposition. The persistent functions of myoFbs lead to fibrotic scars and cardiac dysfunction. The anti-fibrotic treatment is hindered by the elusive mechanism of fibrosis and lack of specific targets on myoFbs. In this review, we will outline the progress of cardiac fibrosis and its contributions to the heart failure. We will also shed light on the role of myoFbs in the regulation of adverse remodeling. The communication between myoFbs and other cells that are involved in the heart injury and repair respectively will be reviewed in detail. Then, recently developed therapeutic strategies to treat fibrosis will be summarized such as i) chimeric antigen receptor T cell (CAR-T) therapy with an optimal target on myoFbs, ii) direct reprogramming from stem cells to quiescent CFs, iii) "off-target" small molecular drugs. The application of nano/micro technology will be discussed as well, which is involved in the construction of cell-based biomimic platforms and "pleiotropic" drug delivery systems.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.addr.2021.03.021DOI Listing
April 2021

The characterization of optimal selenized garlic polysaccharides and its immune and antioxidant activity in chickens.

Int J Biol Macromol 2021 Apr 5. Epub 2021 Apr 5.

School of Veterinary Medicine, Yangzhou University, Yangzhou 225009, PR China; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou 225009, PR China; Joint International Research Laboratory of Agriculture and Agri-Product Safety, the Ministry of Education of China, Yangzhou University, Yangzhou, Jiangsu 225009, PR China. Electronic address:

The purpose of this study was to optimize modification conditions of selenized garlic polysaccharides (sGPS) and investigate its structural characterization, immune and antioxidant activities. Herein, selenized garlic polysaccharides (sGPS) were prepared using by HNO-NaSeO selenylation method. And then modification conditions of sGPS were optimized through L (3) orthogonal test. The structural characterization of sGPS were identified by the Fourier-transform infrared (FT-IR), Solid-State nuclear magnetic resonance (NMR) spectra, X-ray diffraction (XRD) and thermogravimetric (TGA). The morphology of sGPS was detected using scanning electron microscope (SEM) and transmission electron microscope (TEM). In vivo investigation showed that sGPS significantly improved serum hemagglutination-inhibition (HI) antibody titers against Newcastle disease virus, enhanced secretory IgA (sIgA), IFN-γ, IL-2 secretion in jejunum and trachea irrigation compared with vaccine immunized control group. Furthermore, it showed that sGPS had some effects on the antioxidant activities in livers of chickens. In conclusion, the optimal modification conditions of sGPS were as follows: reaction temperature was 70 °C, the dosage of NaSeO was 400 mg and reaction time was 6 h. The selenylation modification of garlic polysaccharides (GPS) could improve its immune and antioxidant activity in chickens.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijbiomac.2021.03.197DOI Listing
April 2021

Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy.

Expert Rev Anticancer Ther 2021 Apr 8. Epub 2021 Apr 8.

Department of Neurology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, 310014, P.R. China.

Introduction: Toll-like receptor-9(TLR9) can recognize the foreign unmethylated CpG DNA, and thus intrigue a strong Th1 response which plays a crucial role in the innate and adaptive immune responses. To date, CpG oligodeoxynucleotide (ODN)-based TLR9 agonists have undergone four generations. Each generations' breakthroughs in immune activation, safety profiles and pharmacokinetic properties were confirmed by both preclinical and clinical studies.

Areas Covered: We reviewed the development and major clinical trials of TLR9 agonists and summarized the optimization strategies of each generation. The applications, limitations and prospects of TLR9 agonists in cancer immunotherapy were discussed were also discussed.

Expert Opinion: Clinical trials of CpG ODN TLR9 agonists as a single agent demonstrated insufficient efficacy to reverse the immunosuppressive status of majority of patients with high tumor burden. Therefore, more efforts are now been carried out in combination with chemotherapy, radiotherapy, immunotherapy maintenance therapy as well as vaccine adjuvant. Importantly, the synergistic and complementary effect of TLR9 agonists and tumor immune checkpoint inhibitor therapy is expected to exert greater potential. On the other hand, the double-edged sword effect of TLR9 activation in tumor and toxic effect reported in combination therapies should be noted and further studies required.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2021.1915136DOI Listing
April 2021